

9-12-12
FOR OFFICIAL USE ONLY

ACCESS DB # 202673
PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: SABITA GAZ Examiner #: 74141 Date: 9/22/05
Art Unit: 1616 Phone Number: 2-0622 Serial Number: 10/634,125
Location (Bldg/Room#): (Mailbox #): Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following: M9

Title of Invention: Plasma Volume expanding formula
Inventors (please provide full names): KAZU NOBU OKAZAKI

Earliest Priority Date: 9/22 8/5/03

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Ch 1-4

Please search for a gel composition
containing protein as in cl 1
further containing masking agent (cl 2)
and/or Vitamin D (cl 3)

Food containing such composition
(cl 4)

copy of claims attached

Thank you

STAFF USE ONLY

Searcher: Mble

Searcher Phone #:

Searcher Location:

Date Searcher Picked Up: 9/27/06

Date Completed: 9/27/06

Searcher Prep & Review Time: 5

Online Time: 50

Type of Search

NA Sequence (#)

AA Sequence (#)

Structure (#)

Bibliographic

Litigation

Fulltext

Other

Vendors and cost where applicable

STN Dialog

Questel/Orbit Lexis/Nexis

Westlaw WWW/Internet

In-house sequence systems

Commercial Oligomer Score/Length
Interference SPDI Encode/Transl
Other (specify)

=> b wpix

FILE 'WPIX' ENTERED AT 15:42:02 ON 27 SEP 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 22 SEP 2006 <20060922/UP>
MOST RECENT DERWENT UPDATE: 200661 <200661/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
<http://scientific.thomson.com/media/scpdf/ipcrdwp.pdf> <<<

>>> FOR FURTHER DETAILS ON THE FORTHCOMING DERWENT WORLD PATENTS
INDEX ENHANCEMENTS PLEASE VISIT:
http://www.stn-international.de/stndatabases/details/dwpi_r.html <<<
'BIX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d all abex abeq tech l45 tot

L45 ANSWER 1 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2006-497114 [51] WPIX

DNC C2006-155633

TI Gelatinized nutrient preparation useful as liquid nutritive supplement,
comprises protein, lipid, carbohydrate, vitamin and/or minerals e.g.
calcium and magnesium and citric acid, and is obtained by performing
retort sterilization.

DC B04 B07 D13

IN KAWAKAMI, K; MIYASHITA, K; MIZUGAI, K

PA (SAKA) OTSUKA SEIYAKU KOGYO KK

CYC 1

PI JP--2006182767 A 20060713 (200651)* 15 A61K-009-06

ADT JP--2006182767 A 2005JP-0341721 20051128

PRAI 2004JP-0349283 20041202

IC ICM A61K-009-06

ICS A61K-038-00; A61K-038-28; A61K-045-00;
A61K-047-12; A61K-047-36; A61P-003-00

AB JP2006182767 A UPAB: 20060809

NOVELTY - A gelatinized nutrient preparation comprises protein, lipid,
carbohydrate, vitamin and/or minerals such as calcium and magnesium and
citric acid and/or citrate, and is obtained by performing retort
sterilization.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for
manufacture of the gelatinized nutrient preparation.

USE - The nutrient preparation is useful as a liquid nutritive
supplement for oral or enteral nutrition.

ADVANTAGE - The gelatinized nutrient preparation is highly stable and
homogenous. The aggregation and isolation of protein in the liquid food is
suppressed effectively.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B03-L; B04-B01B; B04-C01; B04-C02; B05-A01B;
B10-C02; B14-E11; D03-H01T2B; D03-H01T5

L45 ANSWER 2 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2004-527081 [51] WPIX

DNC C2004-193878

TI Gelatin-free articles for stable storage of liquid fillings, especially
capsules containing anhydrous solutions of water-sensitive

active agents, having shell of plasticized biopolymer, preferably starch.

DC A96 B07

IN FREIER, R

PA (SWCA-N) SWISS CAPS RECHTE & LIZENZEN AG

CYC 104

PI EP-----1437129 A1 20040714 (200451)* GE 18 A61K-009-48
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
 MC MK NL PT RO SE SI SK TR
 WO--2004062650 A2 20040729 (200451) GE A61K-009-48
 RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
 LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA
 ZM ZW
 AU--2003294967 A1 20040810 (200479) A61K-009-48
 JP--2006514062 W 20060427 (200628) 26 A61K-009-48
 AU--2003294967 A8 20051103 (200634) A61K-009-48

ADT EP-----1437129 A1 2003EP-0405005 20030108; WO--2004062650 A2
 2003WO-EP014950 20031229; AU--2003294967 A1 2003AU-0294967 20031229;
 JP--2006514062 W 2003WO-EP014950 20031229, 2004JP-0566044 20031229;
 AU--2003294967 A8 2003AU-0294967 20031229

FDT AU--2003294967 A1 Based on WO--2004062650; JP--2006514062 W Based on
 WO--2004062650; AU--2003294967 A8 Based on WO--2004062650

PRAI 2003EP-0405005 20030108

IC ICM A61K-009-48
 ICS A61K-031-551; A61K-038-00; A61K-047-10; A61K-047-36;
 A61K-047-38

AB EP 1437129 A UPAB: 20040810
 NOVELTY - New shaped articles (I) comprise: (A) a gelatin-free shell
 containing at least one first biopolymer (Bp1) and at least one
 plasticizer (PL); and (B) a liquid filling having a water
 content (up to the time that an equilibrium is set up between the
 water contents of (A) and (B)) of less than 3 weight %.
 DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for the
 preparation of (I).
 USE - The use of (I) is claimed in the production of storage-stable
 medicaments containing sparingly water-soluble or water
 -sensitive active agents. (I) is specifically a soft capsule (preferably a
 multi-chamber capsule, especially a two-chamber capsule); and specifically
 contains at least one sparingly water-soluble or water
 -sensitive active agent, especially cyclosporin, isotretinoin, ibuprofen,
 temazepam, nifedipine, nimodipine, paracetamol or codeine (all claimed).
 ADVANTAGE - (I) provide an easily prepared dosage form for solutions
 of water-insoluble active agents, which cause no significant
 precipitation of the active agent due to migration of water from
 (A) into (B) even on long-term storage (since (A) has both a low
 water content and a low tendency to absorb water from
 the environment).
 Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: A12-S; A12-V01; B02-C01; B03-A; B04-A04; B04-B01B;
 B04-B01C; B04-C02; B04-C02B; B04-C02B2;
 B04-C02C; B04-C02D; B04-C03C; B04-N04; B06-D07;
 B07-A02B; B07-D03; B07-D04D; B10-A07; B10-C04C; B10-D03; B10-E04C;
 B12-M11C; B12-M11L

ABEX UPTX: 20040810
 EXAMPLE - A thermoplastic mixture was prepared in an extruder from a
 mixture of 50.2 parts hydroxypropylated starch (in native granular form,
 containing 21% moisture and 0.1 mol. % hydroxypropyl groups), 37.5 parts
 sorbitol syrup (70% solids), 1.1 part liquid lecithin and 1.2 parts
 glycerol monostearate, the mixture having an overall water
 content before extrusion of 23.8% and a water content at the end
 of the process of 11.5% (in equilibrium with atmospheric moisture at

25degreesC and 60% relative humidity). The mixture was melted at 95-105degreesC and extruded to a 0.7 mm strip, which was formed by rotary die methods into soft capsules having a filling prepared by dissolving temazepam in a mixture of polyethylene glycol and propylene glycol. The capsules were conditioned in air containing ca. 50% moisture at 20-30degreesC for 18 hours. A filling was prepared by dissolving temazepam in a mixture of polyethylene glycol 400 and propylene glycol, each capsule containing 20 mg temazepam, 470 mg polyethylene glycol 400 and 43 mg propylene glycol. The water content of the filling after 24 hours was 2.05%, compared with 5.88% for the same filling in a conventional gelatin capsule.

TECH UPTX: 20040810

TECHNOLOGY FOCUS - POLYMERS - Preferred Composition: BP1 is starch, specifically starch or modified starch in native or crystalline, non-destructive form, preferably having an amylopectin content of at least 50 wt. % (based on anhydrous starch) and a moisture content of 10-30 (especially 15-23) wt. %. PL is selected from glycerol, syrups of polyol-containing starch degradation products, sorbitol, maltitol, erythritol, xylitol, trace reducing sugars, propylene glycol, polyglycerol, polysorbitan, polyethylene glycol, ethylene-propylene copolymers, sorbitan fatty acid esters and/or N-methyl-pyrrolidone. (A) optionally also contains at least one second biopolymer (BP2) selected from starch, modified starch, cellulose, partially hydroxypropylated cellulose, alginate, pectin, agar, carrageenan (specifically lambda, iota- or kappa-carrageenan), galactomannan (specifically guar or carob flour), xanthan gum, tamarind, tragacanth gum, karaya gum, chitosan, glucomannan, casein, dextrin, maltodextrin, cyclodextrin, pullulan or arabino-galactan; and/or other additive. The surface of (I) is optionally coated with a lipophilic, waxy or polymeric sealant, specifically selected from beeswax, carnauba wax, candellila wax, berry wax, oxidized polyethylene glycol wax, montanic acid ester, shellac, edible fatty acid mono-, di- or triglycerides or sugar esters of edible fatty acids, dimethyl polysiloxane, acrylic ester and cellulose esters or ethers (or derivatives).

Preparation: Claimed preparation of (I) involves:

- (1) mixing powdered or granular BP1 with liquid PL (preferably in syrup form), optionally together with additives;
- (2) melting the obtained homogeneous crude mixture with heating, optionally under elevated pressure, in a processing apparatus (preferably an extruder) to give a thermoplastic processable mass;
- (3) optionally forming an intermediate product (preferably granules) by cooling and again forming a thermoplastic processable mass;
- (4) forming a film from the mass (preferably by extrusion through a slit die); and
- (5) forming the film into (A) by an intermittent or continuous process at a forming station (especially a rotary die encapsulating machine) and filling (A) with (B), provided that (A) is not subjected to drying after leaving the forming station.

Preferably the melting stage is carried out at 80-180degreesC under a pressure at least corresponding to the vapor pressure at this temperature, water vapor being discharged in a decompression zone or water being injected in an injection zone; film formation is carried out by extrusion under a pressure of more than 50000 Pa and/or at 80-105degreesC from a slit die in an atmospheric environment; and the obtained film is of thickness 0.2-2 mm.

L45 ANSWER 3 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2002-435297 [46] WPIX

CR 2002-171551 [22]

DNC C2002-123607

TI Use of hexapeptides in the manufacture of a medicament for the treatment of acute renal failure.

DC A96 B04

IN KAPUSTA, D R; PETERSEN, J S

PA (ZEAL-N) ZEALAND PHARM AS

CYC 95

PI WO---200228412 A1 20020411 (200246)* EN 30 A61K-038-00 <--
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ
 LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD
 SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU---200167093 A 20020415 (200254) A61K-038-00 <--
 ADT WO---200228412 A1 2001WO-US041008 20010615; AU---200167093 A
 2001AU-0067093 20010615
 FDT AU---200167093 A Based on WO---200228412
 PRAI 2000US-251665P 20001206; 2000DK-0001486 20001005
 IC ICM A61K-038-00
 AB WO 200228412 A UPAB: 20020823

NOVELTY - Manufacture of a medicament involves use of hexapeptides.

DETAILED DESCRIPTION - Manufacture of a medicament involves use of hexapeptide of formula X-hexapeptide-Y or its salt, hydrate or solvate, where the hexapeptide has an amino acid sequence of formula A1-A2-A3-A4-A5-A6.

A1 = Arg, Lys or His;
 A2 = Tyr, Trp or Phe;
 A3 = Tyr, Asn, Trp or Phe;
 A4 = Lys, Arg or His;
 A5 = Phe, Tyr, Trp, Leu, Val or Ile;
 A6 = Arg, Lys or His;
 X = H or acyl; and
 Y = OH or NH₂.

Each amino acid residue in the hexapeptide may be in the L or D form (preferably L-form).

ACTIVITY - Nephrotropic; Litholytic; Cardiant; Hepatotropic; Antiinflammatory; Antialcoholic; Hypotensive; Hemostatic; Vulnerary; Antiidiarrheic; Antidiabetic; Tranquilizer; Antiarrhythmic; Antibacterial; Immunosuppressive; Antiarteriosclerotic; Anticoagulant; Thrombolytic; Dermatological; Vasotropic; Virucide; Antidiuretic; Gastrointestinal; Antidepressant; Antiallergic; Fungicide; Cytostatic; Antiemetic.

MECHANISM OF ACTION - Nociceptin agonist.

USE - In the manufacture of a medicament for selective water diuresis, for the treatment of hyponatremia, sodium and water retaining conditions, acute renal failure, multiple organ failure and hypokalemia (all claimed). The sodium and water retaining conditions include diseases e.g. congestive heart failure (including systolic and diastolic, high-output and low-output, acute and chronic, right-sided and left-sided and forward and backward), liver cirrhosis (including alcoholic liver disease, post-necrotic cirrhosis caused by infectious disease, inherited metabolic disorders, drugs and toxins or inflammatory diseases, biliary cirrhosis (primary and secondary), cardiac cirrhosis due to prolonged severe right-sided congestive heart failure, metabolic, hereditary or drug-related), nephrotic syndrome related to systemic and renal disease, drugs or toxic induced, hypertension in which the hypertension is primary (idiopathic) or secondary to other eliciting causes such as drugs, toxins or diseases in endocrine glands, kidneys and in the central nervous system, multiple organ failure elicited during hemorrhagic shock including acute renal failure and acute renal failure in which the pathogenesis of the disease is related to either pre-renal or intrinsic renal causes. The acute renal failure includes pre-renal azotemia (e.g. hypovolemia caused by hemorrhage, burns, dehydration, gastrointestinal fluid loss, vomiting, surgical drainage, diarrhea, renal fluid loss, diuretics, osmotic diuresis (e.g. diabetes mellitus), hypoadrenalism, sequestration in extravascular space, pancreatitis, peritonitis, trauma and severe hypoalbuminemia), low cardiac output including diseases of myocardium, valves, and pericardium, arrhythmias, tamponade, pulmonary hypertension, massive pulmonary embolus, positive pressure mechanical ventilation, altered renal systemic vascular resistance ratio, renal hypoperfusion with impairment of renal autoregulatory responses, hyperviscosity syndrome (rare) and polycythemia. The acute renal failure also includes intrinsic renal azotemia, due to the

conditions of renovascular obstruction (bilateral or unilateral with one functioning kidney) including renal artery obstruction (e.g. atherosclerotic plaque, thrombosis, embolism, dissecting aneurysm and vasculitis), renal vein obstruction and compression, disease of glomeruli or renal microvasculature including glomerulonephritis and vasculitis, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, disseminated intravascular coagulation, toxemia of pregnancy, accelerated hypertension, radiation nephritis, systemic lupus erythematosus, scleroderma, acute tubular necrosis including ischemia, as for pre-renal azotemia (hypovolemia, low cardiac output, renal vasoconstriction, systemic vasodilatation), obstetric complications (abruptio placentae, postpartum hemorrhage), and toxins including exogenous, antibiotics, chemotherapy and endogenous e.g. myeloma, interstitial nephritis including allergic, antibiotics, infection, bacterial (e.g. acute pyelonephritis, leptospirosis), viral (e.g. cytomegalovirus), fungal (e.g. candidiasis), infiltration and idiopathic, intratubular deposition and obstruction and renal allograft rejection.

ADVANTAGE - The medicament increases urine flow and prevents renal sodium loss.

Rats were infused with isotonic saline (control)/Hexapeptides (test) for 15 minutes prior to anesthesia. Then the animals were anesthetized with isoflurane (3% in O₂/N₂O mixture) and subjected to surgery, hemorrhage and recovery. Consecutive 10 minutes urine samples were collected and rats were allowed to recover for 7 days. Following the hemorrhagic event, urine collections and blood samples were collected on 2, 4 and 6 days, to evaluate the recovery as determined by urine production, and serum concentrations of creatinine and urea. Finally on day 7, rats were sacrificed for histological examination of all organs, using the gentamicin-induced acute renal failure model of D de Rougemont, A Oeschger, L Konrad, G Thiel, J Torhorst, M Wenk, P Wunderlich, F P Brunner, Nephron 1981, 29 176 - 184. The treatment with the test compound prevented multiple organ failure and increased survival after a hemorrhagic event elicited during anaesthesia.

Dwg.0/2

FS CPI

FA AB; DCN

MC CPI: A12-V01; B04-B01B; B04-B01C1; B04-C01B; B04-C02;
B04-C02B1; B04-C02D; B04-C03C; B04-N02; B05-A01B;
B05-B01P; B05-B02C; B07-A02B; B10-C04E; B10-D03; B14-A01; B14-A02;
B14-A04; B14-F02B; B14-H01; B14-N10; B14-N12; B14-N14

ABEX UPTX: 20020722

SPECIFIC PEPTIDES - One derivatized peptide is specifically claimed, i.e. Ac-RYYRWK-NH₂.

ADMINISTRATION - The medicament is administered orally in a unit dosage of 10-100 mg and as an injection in a unit dosage of 0.1-10 mg. The medicament is administered in a dosage of 0.001-10 g/day intravenously, continuously or as a bolus injection, intramuscularly, subcutaneously, intranasally or pulmonary (all claimed), intraperitoneally, rectally, epidurally, intratracheally, dermally, vaginally, buccally, ocularly or by pulmonary administration.

DEFINITIONS - Preferred Definitions:

X = acetyl or trifluoroacetyl; and

Y = NH₂.

TECH UPTX: 20020722

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Sequence: The hexapeptide includes the amino acid sequence of formula (RK)YY(RK)(WI)(RK) (in which the alternative amino acid residues at positions 4, 5 and 6 are shown in brackets) selected from RYYRWR, RYYRWK, RYYRIK, RYYRIR, RYYKIK, RYYKIR, RYYKWR or RYYKWK (preferably RYYRWR, RYYRWK, RYYRIK, RYYKWR or RYYKWK, especially RYYRWK). Preferred Medicament: The medicament further comprises a solid carrier selected from lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid or lower alkyl ether of cellulose and a liquid carrier selected from syrup, peanut oil, olive oil, phospholipid, fatty acid, fatty acid amine, polyoxyethylene or water.

L45 ANSWER 4 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 AN 2000-423196 [36] WPIX
 CR 2000-389642 [34]
 DNC C2000-128057
 TI Carrier composition for biologically active compounds e.g. taxol comprises
 amphipathic lipid and associated polymeric material.
 DC A96 B07
 IN LEIGH, M L S; LEIGH, S
 PA (PHAR-N) PHARES PHARM RES NV
 CYC 91
 PI WO---200033817 A1 20000615 (200036)* EN 43 A61K-009-14
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SZ TZ UG ZW
 W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES
 FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS
 LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
 TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU---200017878 A 20000626 (200045) A61K-009-14
 EP-----1137402 A1 20011004 (200158) EN A61K-009-14
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 JP--2002532389 W 20021002 (200279) 43 A61K-047-24
 ADT WO---200033817 A1 1999WO-GB004070 19991208; AU---200017878 A
 2000AU-0017878 19991208; EP-----1137402 A1 1999EP-0961183 19991208,
 1999WO-GB04070 19991208; JP--2002532389 W 1999WO-GB04070 19991208,
 2000JP-0586310 19991208
 FDT AU---200017878 A Based on WO---200033817; EP-----1137402 A1 Based on
 WO---200033817; JP--2002532389 W Based on WO---200033817
 PRAI 1999GB-0025365 19991027; 1998GB-0027006 19981208
 IC ICM A61K-009-14; A61K-047-24
 ICS A61K-009-20; A61K-009-48; A61K-031-015; A61K-031-122; A61K-031-337;
 A61K-031-352; A61K-031-355; A61K-031-436; A61K-031-727;
 A61K-038-00; A61K-038-23; A61K-038-28;
 A61K-047-18; A61K-047-26; A61K-047-32; A61K-047-36; A61K-047-38;
 A61K-047-42; A61P-003-02; A61P-005-18; A61P-005-50; A61P-007-02;
 A61P-009-04; A61P-035-00; A61P-037-06
 AB WO 200033817 A UPAB: 20021209
 NOVELTY - Carrier composition comprises at least one single and/or double
 chain amphipathic lipid and a polymeric material associated with and
 hardening the lipid.
 DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the
 following:
 (a) a lipid composition for administration to a living organism which
 comprises a biologically active compound and monoacyl and diacyl membrane
 lipid in association with a polymer and is solid and when stored in a
 glass container remains free flowing after storage for 3 months at 40 deg.
 C and 75% relative humidity and
 (b) preparation of the compositions.
 USE - Used as carriers for biologically active compounds preferably
 cyclosporin A, taxol, tacrolimus, rapamycin, insulin, calcitonin, heparin,
 ubiquinone, a tocopherol, a carotenoid or a bioflavanoid, which can be
 formulated as powders or granules.
 ADVANTAGE - The compositions have improved physical characteristics
 and higher loading capacity for lipophilic and hydrophilic compounds. The
 compositions are stable, compact, have good bioavailability and can be
 used for oral administration.
 Dwg.0/2
 FS CPI
 FA AB; DCN
 MC CPI: A12-V01; B02-C01; B03-A; B03-H; B03-K; B04-B01B;
 B04-C02A2; B04-C02B; B04-C02D;
 B04-C02E; B04-C02E3; B04-C03B; B04-D01; B04-J03A;
 B04-J04A; B04-L02; B04-N02; B05-B01P; B06-A03; B06-E05; B07-A02B;
 B10-E04C; B10-G02
 ABEX UPTX: 20000801

EXAMPLE - Griseofulvin was suspended in an ethanolic solution of lipid (phosphatidylcholine: monoacyl phosphatidylcholine weight ratio 33:66) and methacrylic acid copolymer in a weight ratio of griseofulvin: lipid: polymer of 10:5:2.5 and the suspension was vacuum dried for 6 hours at 50degreesC to remove the ethanol and give a griseofulvin containing associate as an off-white flowable powder. The powder could be compressed into tablets or filled into hard gelatin capsules.

TECH

UPTX: 20000801

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred composition: The carrier composition comprises:

- (1) lipids which have GRAS (generally regarded as safe) status preferably a monoacyl or diacyl membrane lipid or an enzyme digested lecithin (especially containing 60-80 mol% monoacyl lipid);
 - (2) 10 wt.% natural gum or its derivative or a synthetic polymer preferably containing cationic or anionic groups, especially a salt of carboxymethylcellulose, alginic acid or its salt, a starch modified with anionic groups, agar, carrageenan, gum arabic, gum tragacanth, gum xanthan, pectin, carboxypolymethylene, a methyl vinyl ether/maleic acid copolymer, an ammonio methacrylate copolymer, chitosan, a methacrylic acid copolymer or a hydrolysed gelatin;
 - (3) a sugar;
 - (4) a polyol, sucrose ester or polyglyceryl ester of a higher fatty acid or another polyol ester of a higher fatty acid and
 - (5) a biologically active compound in a weight ratio to lipid of 40:1-1:40, as a molecular dispersion in the lipid or as discrete particles in the composition (preferably of size less than or equal to 1 mum).
- The composition is formulated as powder of size 50-2000 mum or as granules of size 1-5 mm.

The lipid composition comprises lipids which have GRAS status, preferably an optionally enzyme modified natural lipid (especially derived from egg or soya), a semi-synthetic lipid or a synthetic lipid and a natural polysaccharide polymer, starch or their derivatives, cellulose or its derivatives or gelatin.

Preparation: The composition is prepared by dissolving or dispersing ingredients in a solvent and removing the solvent, preferably preparation comprises dissolving the lipid and active agent in ethanol, dissolving the polymer in water, mixing the aqueous and ethanolic solutions, drying the mixture, comminuting the composition and forming the mixture into a tablet or capsule.

L45 ANSWER 5 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1997-140816 [13] WPIX

DNN N1997-116617 DNC C1997-044944

TI Infusion solution for venous administration - comprises sugar, amino acids, electrolyte and fat.

DC B05 P33

PA (SAKA) OTSUKA SEIYAKU KOGYO KK

CYC 1

PI JP----09020650 A 19970121 (199713)* 11 A61K-009-08

ADT JP----09020650 A 1995JP-0167538 19950703

PRAI 1995JP-0167538 19950703

IC ICM A61K-009-08

ICS A61J-001-05; A61K-031-195; A61K-031-23; A61K-031-40; A61K-031-405;
A61K-031-415; A61K-031-70; A61K-033-00; A61K-033-06;
A61K-033-14; A61K-033-30; A61K-033-42; A61K-038-00

ICI A61K-031-195, A61K-031:23, A61K-031:70, A61K-033:

AB JP 09020650 A UPAB: 19970326

Infusion solution for venous administration is composed of sugar, at least 8 essential amino acids, an electrolyte and fat, adjusted to pH 6.5-7.4, administered in peripheral vein at doses of 1,000-1,500 kcal such that the osmotic pressure ratio is at most 0.8+(6/square root of daily administration period).

The daily dose is 2,000-2,500 ml. The daily administration period is 6-18 hrs.. Calories of fat occupy less than 50% of total calories. The infusion solution contains 40-90 g/l of glucose, 15-35 g/l of fat, 20-45 g/l of total amino acids expressed by g/l as a free state composed of 3.0-5.0

of L-Leu, 1.5-3.0 each of L-Ile, L-Val and L-Ala, 2.0-3.8 each of L-Lys and L-Arg, 1.0-2.0 each of L-Thr, L-His and L-Pro, 0.3-1.0 of L-Tyr, 0.6-1.5 of L-Met, 1.2-2.5 of L-Phe, 0-0.5 of L-CySH or L-Cys, L-Asp and L-Glu, 0-0.4 of L-Tyr, 0.5-1.3 of L-Ser, and 1.0-2.3 of Gly, and electrolytes expressed by mEq/L composed of 25-45 of Na, 10-30 of K, 2-8 each of Ca and Mg, 10-20 of Cl, 0-15 mmol of P and 0-10 micro mol of Zn. Daily administration period is 8-12 hrs.. The infusion solution in which glucose and amino acids are separately packed in a container with a partition wall fitted with a connecting channel for use. The infusion solution is separately packed in 2 portions in which fat and glucose or amino acids are filled in 1 portion and electrolytes containing bivalent cation(s) is/are contained separately. The infusion solution is separately packed in 3 portions in which glucose, amino acids and fat are separately filled in different containers and the electrolyte(s) is/are contained together with glucose and/or amino acids. The gas permeable flexible plastic container has an easily peelable partition wall and is folded at the site of the wall and contained in a gas difficultly permeable container with a deoxygenation agent.

ADVANTAGE - Safe infusion solution with phlebitis preventive effect.

Dwg.0/0

FS CPI GMPI

FA AB; DCN

MC CPI: B04-B01B; B10-A07; B10-B02C; B14-F02

L45 ANSWER 6 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1996-020333 [02] WPIX

DNC C1996-006964

TI Microemulsion based gel compsn. - can be used for both lipophilic and hydrophilic active components.

DC B05 B07

IN BACKLUND, S; ERIKSSON, F; RANTALA, M; RANTALA, P; VARHO, K

PA (LEIR-N) LEIRAS OY

CYC 65

PI WO-----9531969 A1 19951130 (199602)* EN 32 A61K-009-107

RW: AT BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT SD SE SZ UG

W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE

KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE

SG SI SK TJ TM TT UA UG US UZ VN

FI-----9402387 A 19951125 (199607) A61K-009-10

AU-----9523091 A 19951218 (199611) A61K-009-107

EP-----760651 A1 19970312 (199715) EN A61K-009-107

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

FI-----100692 B1 19980213 (199812) A61K-009-10

JP----10500675 W 19980120 (199813) 30 A61K-009-107

US-----6004580 A 19991221 (200006) A61K-009-66

EP-----760651 B1 20010704 (200138) EN A61K-009-107

R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DE----69521611 E 20010809 (200153) A61K-009-107

ES-----2160161 T3 20011101 (200175) A61K-009-107

ADT WO-----9531969 A1 1995WO-FI000234 19950428; FI-----9402387 A

1994FI-0002387 19940524; AU-----9523091 A 1995AU-0023091 19950428;

EP-----760651 A1 1995EP-0916686 19950428, 1995WO-FI00234 19950428;

FI-----100692 B1 1994FI-0002387 19940524; JP----10500675 W 1995JP-0530069

19950428, 1995WO-FI00234 19950428; US-----6004580 A 1995WO-FI00234

19950428, 1997US-0727545 19971112; EP-----760651 B1 1995EP-0916686

19950428, 1995WO-FI00234 19950428; DE----69521611 E 1995DE-0621611

19950428, 1995EP-0916686 19950428, 1995WO-FI00234 19950428; ES-----2160161

T3 1995EP-0916686 19950428

FDT AU-----9523091 A Based on WO-----9531969; EP-----760651 A1 Based on

WO-----9531969; FI-----100692 B1 Previous Publ. FI-----9402387;

JP----10500675 W Based on WO-----9531969; US-----6004580 A Based on

WO-----9531969; EP-----760651 B1 Based on WO-----9531969; DE----69521611

E Based on EP-----760651, Based on WO-----9531969; ES-----2160161 T3

Based on EP-----760651

PRAI 1994FI-0002387 19940524

REP 01Jnl.Ref; GB---2222770; WO---8602264

IC ICM A61K-009-10; A61K-009-107; A61K-009-66
 ICS A61K-009-06; A61K-009-127; A61K-009-64; A61K-047-36; A61K-047-42
 AB WO 9531969 A UPAB: 19960115
 A microemulsion compsn. comprising a hydrophilic component, a lipophilic component, a surfactant and a drug is new. The hydrophilic component, the lipophilic component and the surfactant form, on a macroscopic scale, a one-phase solution wherein (a) the hydrophilic component is dispersed as colloidal droplets in the lipophilic component, or (b) the lipophilic component is dispersed as colloidal droplets in the hydrophilic component, or (c) the hydrophilic and the lipophilic components form a microemulsion with bi-continuous structure wherein the components form elongated intertwined channels, and (d) the drug is dissolved in the dispersed component or in the hydrophilic or the lipophilic component of a microemulsion of bicontinuous structure, and the microemulsion is stabilized by the surfactant, wherein a gelatiniser (gelatin or a polysaccharide) and water are added to the microemulsion thereby bringing the microemulsion into gel form.
 ADVANTAGE - The compsn. can be used for the immobilisation of both lipophilic and hydrophilic substances.
 Dwg.0/5
 FS CPI
 FA AB; DCN
 MC CPI: B02-C; B03-L; B04-B01B; B04-B01C3; B04-C02D;
 B05-B01P; B10-A07; B10-E04C; B12-M03; B12-M07

L45 ANSWER 7 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 AN 1993-322126 [41] WPIX
 DNC C1993-143227
 TI High protein liquid nutrition formula aids wound healing - especially for patients requiring long-term tube feeding.
 DC B05 D13
 IN LIN, P M; TRIMBO, S; TWYMAN, D; TRIMBO, S L
 PA (CLIN-N) CLINTEC NUTRITION CO
 CYC 19
 PI EP-----564804 A1 19931013 (199341)* EN 8 A23L-001-305
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
 CA-----2093453 A 19931011 (199402) A23L-001-304
 JP----06048954 A 19940222 (199412) 6 A61K-037-02
 AU-----9333745 A 19940414 (199420) A23L-001-305

ADT EP-----564804 A1 1993EP-0103174 19930227; CA-----2093453 A 1993CA-2093453
 19930406; JP----06048954 A 1993JP-0084352 19930412; AU-----9333745 A
 1993AU-0033745 19930224

PRAI 1992US-0866833 19920410
 REP EP---259167; EP---298179; EP---395865; EP---511895; JP--61135571;
 WO---8801861

IC ICM A23L-001-304; A23L-001-305; A61K-037-02
 ICS A23D-007-02; A23L-001-302; A23L-001-303; A61K-009-08; A61K-031-07;
 A61K-031-185; A61K-031-20; A61K-031-205; A61K-031-355; A61K-031-375;
 A61K-031-51; A61K-031-70; A61K-033-04; A61K-033-30

AB EP 564804 A UPAB: 19931130
 High-protein liquid nutrition formula (I) for the treatment of patients with increased wound-healing requirements comprises: (a) a protein source; (b) a fat source; (c) a carbohydrate source; (d) at least 500% of the U.S. RDA of Vitamin C per 1000 Kcal of the formula; and (e) at least 145% of the U.S. RDA of Vitamin A per 1000 Kcal of the formula. Other vitamins, trace elements and dietary fibre may be present.
 USE/ADVANTAGE - (I) is useful in improving wound healing in patients suffering from trauma, cancer, burns, pressure or vascular ulcers, in the case of post operative recovery and where wound healing is complicated by a lean body mass loss of greater than 15%. Dosage is 2000 Kcal/day/patient.
 (I) provides high levels of protein (greater than the U.S. RDA per 1000 Kcal) to enhance wound healing capabilities in conjunction with elevated levels of zinc and Vitamin C. Other ingredients are provided to reduce immune suppression and to overcome difficulties encountered with patients requiring long-term tube feeding.
 Dwg. 0/0

FS CPI
 FA AB; DCN
 MC CPI: B03-A; B03-B; B03-F; B04-B01B; B04-B04A6;
 B04-C02D; B05-A03A; B10-G02; B12-A01; B12-A06; B12-A07;
 B12-G07; D03-H01T

L45 ANSWER 8 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1992-358911 [44] WPIX

CR 1995-312557 [41]; 1997-067270 [07]

DNC C1992-159329

TI Storage-stable infusion compsn. for parenteral feeding - comprises fat emulsion, sugar, aminoacid(s), electrolyte and phosphate of poly hydric alcohol or sugar, with pH adjusted with organic acid.

DC B07 D13 P33

IN ABE, S; INOUE, T; KODAIRA, H; MURASHIMA, R; NAWA, Y; YOKOYAMA, K

PA (GREC) GREEN CROSS CORP; (MITS-N) MITSUBISHI PHARMA CORP; (MITS-N) MITSUBISHI PHARM CORP; (YOSH) YOSHITOMI PHARM IND KK; (WELF-N) WELFIDE CORP

CYC 16

PI EP-----510687 A2 19921028 (199244)* EN 33 A61K-009-00
 R: BE CH DE DK ES FR GB IT LI NL SE
 CA-----2067062 A 19921027 (199303) A61K-009-107
 JP-----05009111 A 19930119 (199311) 6 A61K-009-107
 JP-----05031151 A 19930209 (199311) 12 A61J-001-05
 JP-----05032540 A 19930209 (199312) 11 A61K-009-107
 JP-----05032541 A 19930209 (199312) 6 A61K-009-107
 JP-----05065220 A 19930319 (199316) 8 A61K-009-107
 JP-----05148149 A 19930615 (199328) 7 A61K-031-66
 JP-----05301825 A 19931116 (199350) 4 A61K-037-22
 EP-----510687 A3 19930512 (199402) A61K-009-00
 US-----5626880 A 19970506 (199724) 15 A61K-009-14
 US-----5674527 A 19971007 (199746) 16 A61K-009-127
 TW-----320563 A 19971121 (199811) A61K-009-08
 JP-----2940249 B2 19990825 (199940) 4 A61K-038-00 <--
 JP-----2950348 B2 19990920 (199944) 6 A61K-009-107
 US-----5972367 A 19991026 (199952) A61K-009-107
 JP-----11343229 A 19991214 (200009) 6 A61K-009-107
 JP-----3097196 B2 20001010 (200052) 7 A61K-009-107
 KR-----244997 B1 20000315 (200122) A61J-001-00
 EP-----510687 B1 20021016 (200276) EN A61K-009-00
 R: BE CH DE DK ES FR GB IT LI NL SE
 US-----6475506 B1 20021105 (200276) A61K-009-107
 DE-----69232811 E 20021121 (200302) A61K-009-00
 JP-----3364932 B2 20030108 (200306) 12 A61J-001-05
 ES-----2181669 T3 20030301 (200322) A61K-009-00
 JP-----3430965 B2 20030728 (200351) 7 A61K-009-107
 JP-----3446035 B2 20030916 (200362) 8 A61K-009-107
 JP-----3456536 B2 20031014 (200369) 13 A61K-009-107
 CA-----2067062 C 20040713 (200447) EN A61K-009-107
 JP-----3711400 B2 20051102 (200572) 10 A61K-031-66
 KR-----489158 B 20050517 (200657) A61K-009-14
 ADT EP-----510687 A2 1992EP-0107054 19920424; CA-----2067062 A 1992CA-2067062
 19920424; JP-----05009111 A 1991JP-0222031 19910806; JP-----05031151 A
 1991JP-0209944 19910726; JP-----05032540 A 1991JP-0209945 19910726;
 JP-----05032541 A 1991JP-0209947 19910726; JP-----05065220 A 1992JP-0027338
 19920117; JP-----05148149 A 1992JP-0131797 19920423; JP-----05301825 A
 1991JP-0222032 19910806; EP-----510687 A3 1992EP-0107054 19920424;
 US-----5626880 A Cont of 1992US-0873229 19920424, Cont of 1993US-0133792
 19931008, 1996US-0589207 19960122; US-----5674527 A Cont of 1992US-0873229
 19920424, Div ex 1993US-0133792 19931008, 1995US-0478970 19950607;
 TW-----320563 A 1992TW-0103293 19920425; JP-----2940249 B2 1991JP-0222032
 19910806; JP-----2950348 B2 1991JP-0222031 19910806; US-----5972367 A Cont
 of 1992US-0873229 19920424, Div ex 1993US-0133792 19931008, 1995US-0475812
 19950607; JP-----11343229 A Div ex 1991JP-0209947 19910726, 1999JP-0102878
 19910726; JP-----3097196 B2 1991JP-0209947 19910726; KR-----244997 B1 Div
 ex 1992KR-0007018 19920425, 1999KR-0023090 19990619; EP-----510687 B1

1992EP-0107054 19920424, Related to 1995EP-0104553 19920424, Related to 1996EP-0115944 19920424; US-----6475506 B1 Cont of 1992US-0873229 19920424, Div ex 1993US-0133792 19931008, Div ex 1995US-0475812 19950607, 1999US-0244931 19990210; DE----69232811 E 1992DE-0632811 19920424, 1992EP-0107054 19920424; JP-----3364932 B2 1991JP-0209944 19910726; ES-----2181669 T3 1992EP-0107054 19920424; JP-----3430965 B2 Div ex 1991JP-0209947 19910726, 1999JP-0102878 19910726; JP-----3446035 B2 1992JP-0027338 19920117; JP-----3456536 B2 1991JP-0209945 19910726; CA-----2067062 C 1992CA-2067062 19920424; JP-----3711400 B2 1992JP-0131797 19920423; KR-----489158 B Div ex 1992KR-0007018 19920425, 1999KR-0062610 19991227

FDT JP-----2940249 B2 Previous Publ. JP----05301825; JP-----2950348 B2 Previous Publ. JP----05009111; JP-----3097196 B2 Previous Publ. JP----05032541; EP-----510687 B1 Related to EP-----671166, Related to EP-----752243; US-----6475506 B1 Div ex US-----5972367; DE----69232811 E Based on EP-----510687; JP-----3364932 B2 Previous Publ. JP----05031151; ES-----2181669 T3 Based on EP-----510687; JP-----3430965 B2 Previous Publ. JP----11343229; JP-----3446035 B2 Previous Publ. JP----05065220; JP-----3456536 B2 Previous Publ. JP----05032540; JP-----3711400 B2 Previous Publ. JP----05148149

PRAI 1992JP-0027338 19920117; 1991JP-0124866 19910426;
1991JP-0124863 19910427; 1991JP-0124739 19910428;
1991JP-0209944 19910726; 1991JP-0209945 19910726;
1991JP-0209946 19910726; 1991JP-0209947 19910726;
1991JP-0222031 19910806; 1991JP-0222032 19910806;
1999JP-0102878 19910726

REP No-SR.Pub; 1.Jnl.Ref; DE---3228127; EP----101185; EP----189160;
GB---1158456; JP--61058560

IC ICM A61J-001-00; A61J-001-05; A61K-009-00; A61K-009-08; A61K-009-107;
A61K-009-127; A61K-009-14; A61K-031-66; A61K-037-22;
A61K-038-00

ICS A23D-007-00; A23D-007-02; A23L-001-30; A61K-009-10; A61K-031-00;
A61K-031-045; A61K-031-047; A61K-031-195; A61K-031-23; A61K-031-405;
A61K-031-415; A61K-031-70; A61K-031-7004;
A61K-033-00; A61K-033-30; A61K-035-78; A61K-047-06; A61K-047-12;
A61K-047-18; A61K-047-22; A61P-003-02; B01F-017-00

ICA A61K-031-19

ICI A61K-031:19, A61K-031:195, A61K-031:40, A61K-031:405, A61K-031:415,
A61K-031:66, A61K-031:70, A61K-033-30, A61K-033:06,
A61K-033:14; A61K-031:19, A61K-031:195, A61K-031:40, A61K-031:405,
A61K-031:415, A61K-031:66, A61K-031:70, A61K-033-30,
A61K-033:06, A61K-033:14; A61K-031:195, A61K-031:40, A61K-031:405,
A61K-031:415, A61K-031:66, A61K-031:70, A61K-033-30,
A61K-033:06, A61K-033:14; A61K-031:195, A61K-031:40, A61K-031:405,
A61K-031:415, A61K-031:66, A61K-031:70, A61K-033-30,
A61K-033:06, A61K-033:14

AB EP 510687 A UPAB: 20060906

The following are claimed (A) an infusion compsn. comprising a sugar, amino acids, electrolytes, a fat emulsion and a phosphate ester (I), where the compsn. is adjusted to pH 5-8 with an organic acid and where (I) is a phosphate ester of a polyhydric alcohol or sugar and is opt. in salt form, (B) a container with two separate compartments, where one compartment is filled with an infusion liquid containing a fat emulsion and a sugar, and the other compartment is filled with an infusion liquid containing amino acids and electrolytes, (C) an infusion compsn. containing a fat emulsion and a sugar, where the compsn. contains 0.1-30% fat, 0.01-10% of an emulsifying agent and 5-60% of a reducing sugar, (D) an infusion compsn. containing amino acids, electrolytes and (I), where the compsn. is adjusted to pH 5-8 with citric, lactic, malic, gluconic, maleic and/or malonic acid, (E) an infusion compsn. containing a fat emulsion, a sugar and at least one buffer selected from L-histidine and Tris, (F) a nutrient-supplying fat emulsion obtainable by emulsifying a fat with an emulsifying agent, where the emulsion contains 0.01-5% of the emulsifying agent and has a mean droplet size of 0.17 micron or less, (G) a process for producing a nutrient-supplying fat emulsion having a mean droplet size of 0.17 micron or less, by emulsifying a fat using an emulsifying agent together with

glycerol and/or glucose, (H) a process for stabilising a fat emulsion by mixing it with a solution containing divalent metal ions in the presence of citric, lactic, malic, gluconic, maleic and/or malonic acid and/or their salts.

USE - The infusion compsns. are useful for parenteral feedingle

Dwg.0/0

FS CPI GMPI

FA AB; DCN

ABEQ JP 05148149 A UPAB: 19931116

The transfusion comprises aminoacids of 1 to 15% (w/v), electrolytes, poly-alcohols or sugar phosphate esters as a phosphorus source, and one or more organic acids of citric acid, lactic acid, malic acid and malonic acid, with pH adjusted to 5.0 to 8.0.

Organic acid is pref. citric acid, and glycerophosphates are pref. used as phosphorus source.

USE/ADVANTAGE - Compsn. is very stable and causes no colouration or sedimentation when heated and sterilised. As the prepn. needs no mixing of aminoacids and electrolytes, it avoids bacterial contamination on mixing. The compsn. is used for nutrition supply for patients.

In an example, the transfusion comprises 1.949 g of sodium chloride, 4.302 g of potassium chloride, 2.054 g of magnesium sulphate.7H₂O, 6.35 g of potassium gluconic acid.H₂O, 8.016 g of glycerophosphoric acid bipotassium (50 %), 11.340 g of sodium acetate.3H₂O and 9.585 mg of zinc sulphate.7H₂O (in 1 litre).

Dwg.0/0

ABEQ US 5626880 A UPAB: 19970612

A process for producing an infusion preparation comprising an infusion liquid containing a nutrient-supplying fat emulsion having a mean particle size of 0.17 µm or less which comprises emulsifying a fat using an emulsifying agent together with one or more compounds present during the emulsification and selected from the group consisting of glycerol and glucose.

Dwg.0/3

ABEQ US 5674527 A UPAB: 19971119

A container with infusion liquids, which container comprises first and second compartments separated from each other by a separation means, wherein an infusion liquid containing a fat emulsion, said emulsion comprising water, a fat and an emulsifying agent, and a sugar is included in the first compartment and another infusion liquid containing amino acids and electrolytes is included in the second compartment.

Dwg.0/3

L45 ANSWER 9 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1991-290172 [40] WPIX

DNC C1991-125444

TI Compressed confection tablet for dissolving in oral cavity - comprises timed release of flavour ingredient intimately bound with bioactive which adheres to moist areas of mouth as tablet dissolves.

DC A96 A97 B07 D13

IN CHERUKURI, S R; MANSUKHANI, G; RAMAN, K P; ORAMA, A M

PA (WARN) WARNER LAMBERT CO; (WARN) WARNER-LAMBERT CO; (CHER-I) CHERUKURI S R; (MANS-I) MANSUKHANI G; (ORAM-I) ORAMA A M; (RAMA-I) RAMAN K P

CYC 20

PI EP-----449782 A 19911002 (199140)*

R: BE CH DE ES FR GB GR IT LI NL SE

AU-----9173873 A 19911003 (199147)

NO-----9101259 A 19911001 (199149)

CA-----2039250 A 19911001 (199151)

PT-----97168 A 19911129 (199201)

FI-----9101498 A 19911001 (199203)

ZA-----9102403 A 19920129 (199209)

CN-----1055292 A 19911016 (199229)

A61K-007-16

JP-----04222555 A 19920812 (199239)

13 A23G-003-00

US-----5284659 A 19940208 (199407)

13 A61K-009-20

ADT EP-----449782 A 1991EP-0810213 19910325; ZA-----9102403 A 1991ZA-0002403 19910328; CN-----1055292 A 1991CN-0102016 19910328; JP-----04222555 A

1991JP-0089176 19910329; US-----5284659 A 1990US-0502464 19900330
 PRAI 1990US-0502464 19900330
 REP 1.Jnl.Ref; DE---2658282; JP--62022552; SE---8004817; US---4789546
 IC ICM A23G-003-00; A61K-007-16; A61K-009-20
 ICS A23L-001-22; A23P-001-02; A61K-009-22; A61K-009-26; A61K-009-28
 AB EP 449782 A UPAB: 19930928
 A compressed confection tablet for dissolving in the oral cavity has timed release of a flavour ingredient and is capable of adhering to the moist areas of the oral cavity and comprises: a flavour ingredient intimately bound with a bioadhesive which adheres to the moist areas of the oral cavity as the compressed tablet dissolves in the cavity.

USE/ADVANTAGE - The flavour and bioadhesive compsn. provides a unique mouthfeel. The tablet provides both a rapid initial delivery as well as timed delivery of flavour ingredients to the oral cavity. The tablet provides heightened and varied organoleptic responses which are pleasing to the consumer.

0/6

FS CPI

FA AB; DCN

MC CPI: A12-W09; B04-B01B; B04-B01C; B04-B04A6;
 B04-C02; B04-C03; B04-D01; B05-A01B; B05-B02A3; B05-C04;
 B10-A07; B12-L04; B12-M10A; B12-M11B; D03-E

ABEQ US 5284659 A UPAB: 19940329

A confectionary tablet having a 2-phase system having separate regions for timed release delivery of active ingredient(s) through buccal route or by releasing an ingredient into the oral activity comprises 82+ wt.%, of hydrophilic component contg. flavour and matrix of polymer systems, gums, gelatin, starches opt. modified, and film formers; and up to 18 wt.% of hydrophobic component comprising active ingredient(s), 1st ingredient, bioadhesive cpd. and hydrophobic encapsulation medium. The 1st ingredient is flavours, sweeteners and mixt. Flavours include spearmint, cinnamon, wintergreen, lemon, orange, grape, lime, grapefruit, banana oils and essences of apple, strawberry, cherry, pineapple, and mixts. Bioadhesive cpds. include amylopectin, carboxymethyl celluloses, hydroxyethyl celluloses, acrylates, gelatin, guar gum, agar, alginic acid, dextran, pectin, etc., in amt. below 1%. Breath fresheners, deodorants, antingivitis agents may be included.

ADVANTAGE - Controlled time release of flavours, etc. which adheres to moist areas of oral cavity. Pleasant mouth feel.

Dwg.0/6

L45 ANSWER 10 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1991-029305 [04] WPIX

CR 1988-177077 [26]; 1990-180496 [24]; 1990-238499 [31]; 1991-116975 [16];
 1991-269005 [37]

DNC C1991-012533

TI Sweetener delivery system - comprising core of sweetener coating material, and outer coating of sweetener-hydrophilic polymer.

DC A97 B05 B07 D13

IN CHAU, T L; CHERUKURI, S R; ORAMA, A M; RAMAN, K P; CHAU, T K

PA (WARN) WARNER-LAMBERT CO; (WARN) WARNER LAMBERT CO

CYC 23

PI US-----4981698 A 19910101 (199104)* 13

EP-----434321 A 19910626 (199126)

R: BE CH DE ES FR GB GR IT LI LU NL SE

AU-----9068113 A 19910627 (199133)

NO-----9005348 A 19910619 (199134)

CA-----2032394 A 19910619 (199135)

FI-----9006224 A 19910619 (199137)

PT-----96219 A 19910930 (199142)

CN-----1052777 A 19910710 (199216)

ZA-----9010147 A 19920826 (199239) 42 A23L-000-00

JP-----06014739 A 19940125 (199408) 15 A23L-001-22

EP-----434321 B1 19950301 (199513) EN 29 A23G-003-30

R: BE CH DE DK ES FR GB GR IT LI LU NL SE

DE-----69017399 E 19950406 (199519) A23G-003-30

ES-----2069031 T3 19950501 (199524) A23G-003-30
CA-----2032394 C 19970506 (199734) A23L-001-236
PH-----28324 A 19940616 (199838) A23G-003-30
JP-----3118781 B2 20001218 (200102) 13 A23G-003-30

ADT US-----4981698 A 1989US-0452660 19891218; EP-----434321 A 1990EP-0313724
19901217; ZA-----9010147 A 1990ZA-0010147 19901217; JP----06014739 A
1990JP-0417734 19901217; EP-----434321 B1 1990EP-0313724 19901217;
DE----69017399 E 1990DE-0617399 19901217, 1990EP-0313724 19901217;
ES-----2069031 T3 1990EP-0313724 19901217; CA-----2032394 C 1990CA-2032394
19901217; PH-----28324 A 1990PH-0041700 19901210; JP-----3118781 B2
1990JP-0417734 19901217

FDT DE----69017399 E Based on EP-----434321; ES-----2069031 T3 Based on
EP-----434321; JP-----3118781 B2 Previous Publ. JP----06014739

PRAI 1989US-0452660 19891218

REP AU-----81410; EP----273009; US---3857964; US---3867556; US---3985913

IC A21D-000-00; A23G-003-30; A23L-001-23; A23P-001-04; A61K-000-00
ICM A23G-003-30; A23L-000-00; A23L-001-22; A23L-001-236
ICS A21D-002-08; A23G-003-00; A23L-001-23; A23P-001-04; A61K-007-16;
A61K-009-68; A61P-001-02

AB US 4981698 A UPAB: 20010110
Sweetener delivery system comprises: (a) 1 or more solid high intensity
sweeteners(I); (b) a hydrophobic or hydrophilic coating (II) mixed with
1-50% by weight (I) to form a core; and (c) an outer coating of a hydrophilic
polymer (III) containing another sweetener (IV) which is prepared from a soln
of (III) and 10-25% by weight (of solution) of (IV). The outer coating is
present at 5-50% of (II).
(I) is an amino acid-based sweetener, chloro-deriv of sucrose,
dihydroflavinol, hydroxyguaiacol ester, L-aminodicarboxylic acid
gemdiamine, L-aminodicarboxylic acid aminoalkenoic acid ester amide,
dipeptide sweetener, glycyrrhizin, saccharin and salt, acesulphame salts,
cyclamate, stevioside, talin, dihydrochalcone or mixts.
(I) is pref. aspartame (1-50% of system), saccharin (or salt; 1-50%
of system), or a mixture of aspartame (up to 25%) and saccharin (1-50%)
which may also comprise 1-50% K acesulphame. Amount of (IV) is pref. 3-15%
by wt.of outer coating. The outer coating pref. comprises a hydrocolloid
(partic gum, pectin, alginate, mucilage, film-forming carbohydrate or
mixts): especially gum arabic, tragacanth, karaya, ghatti, agar,
alginate, carrageenan, fucellan, psyllium, or mixts: or polyvinyl
pyrrolidone, gelatin, dextran, xanthan, curdan, cellulose, Me- or
Et-cellulose, hydroxy-Et-or hydroxy-Pr-cellulose, hydroxy-Pr Me-cellulose,
carboxy-Me cellulose, low-MeO pectin, propylene glycol alginate, or mixts.
Amount of outer coating is pref. 15-50% of (II). Alternative compsns. may
comprise (I), an emulsifier (lecithin, stearates and palmitates and
oleates and glycerides and ester derivs. of these, sucrose polyesters,
polyglycerol esters, and animal, vegetable, synth and petroleum waxes, or
mixts), 20-93% of an inner coating of polyvinyl acetate (mol weight
2000-14,000), and an outer coating of (III) and (IV).
USE/ADVANTAGE - The system effectively provides greater up front
sweetness intensity with prolonged sweetener @ (13pp Dwg.No.0/2)y s
0/2y s

FS CPI
FA AB; DCN

MC CPI: A09-A; A12-W05; A12-W09; B04-B01C; B04-B04A6; B04-C01;
B04-C02D; B04-C03A; B04-C03B; B06-F01; B07-A02; B07-G;
B10-A08; B10-B01B; B10-B02E; B10-E02; B10-F02; B10-G02; B12-J01;
D03-H01A

ABEQ ZA 9010147 A UPAB: 19930928
The delivery system comprises a first high intensity sweetener
encapsulated in a first core coating, and a second outer hydrophilic
coating containing up to the solubility limit of the second coating of a
second sweetener.
USE/ADVANTAGE - The resulting delivery system may be incorporated
into a variety of comestible products including chewing gums and other
confections, baked goods, oral pharmaceuticals and oral hygiene
preparations. Enhanced up front sweetness intensity in combination with
prolonged sweetness duration, and improved protection and stability of the

active

ABEQ EP 434321 B UPAB: 19950404

A sweetener delivery system capable of providing greater up-front sweetness while modulating sweetener release and providing greater protection of the sweetener, the sweetener delivery system comprising: A. at least one inner coating material selected from hydrophobic and hydrophilic coating materials, the inner coating material and the first sweetener being mixed and prepared to form a core in which the first sweetener is present in an amount of from 1% to 50% by weight of the core; and C. a second, outer coating of a hydrophilic polymer containing a second sweetener, the second outer coating being prepared from a solution of the hydrophilic polymer and the second sweetener, with the second sweetener being present in the polymer solution in an amount ranging from 10% to 25% by weight of the solution, the outer coating being present in an amount of from 5% to 50% by weight of the inner coating material.
Dwg.0/2

L45 ANSWER 11 OF 11 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 1988-277653 [39] WPIX

DNN N1988-210908 DNC C1988-123741

TI Delivery unit for plant meristematic tissue - improves germination and root formation.

DC A97 C03 P11 P13

IN MOTEKI, S; MOTOYAMA, S; OGISHIMA, H; UMEDA, S

PA (FREU-N) FREUNT IND CO LTD; (KIRI) KIRIN BREWERY KK

CYC 2

PI US-----4769945 A 19880913 (198839)* 8

JP----62179303 A 19870806 (199028)

ADT US-----4769945 A 1987US-0008737 19870130

PRAI 1986JP-0018066 19860131

IC A01C-001-06; A01G-001-00

AB US 4769945 A UPAB: 19930923

Delivery unit of plant tissue comprises a water-soluble body (I) with an interior covering of a water-insol. material (II) and charged with a hydrogen (III). The vessel contains meristematic tissue with the ability to grow into an entire plant body through differentiation. Pref. the meristematic tissue, namely somatic, zygotic or germ line tissue, is held by (III), so that at least part of it is exposed to the air.

The following prefd. materials are listed in the claims: (I) is of a polymeric substance, e.g. gelatin, casein, starch, pullulan, sodium alginate, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl alcohol, sodium polyacrylate, polyacrylamide, polyoxyethylene and polyvinyl pyrrolidone. (II) is a resin, rubber, cellulose derivative fat, oil or wax. (III) is prepared from agar, sodium alginate, pectin, mannan, carrageenan or gellan gum.

USE/ADVANTAGE - The unit facilitates handling of meristematic tissues until time of planting and improves germination and root formation by supplying sufficient oxygen. Water and nutrients are supplied from the hydrogel. When the delivery unit is seeded, the vessel body is dissolved by water from the field, and the buds and roots from the growing tissue easily break the thin film of (II).

0/7

FS CPI GMPI

FA AB; DCN

MC CPI: A09-A; A12-W04A; A12-W04B; C04-B01B; C04-B01C; C04-B04A2; C04-B04A6; C04-C02; C04-C03; C12-P08

=> => b hcap

FILE 'HCAPLUS' ENTERED AT 15:56:29 ON 27 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005018794	ICM	B01J-0013/04
	ICS	A23L-0001/00
	IPCI	B01J0013-04 [ICM,7]; A23L0001-00 [ICS,7]; B01J0013-04 [ICS,7]
	IPCR	A21D0002-00 [I,C*]; A23B0004-00 [I,C*]; A23B0004-12 [I,C*]; A23B0004-14 [I,C*]; A23B0005-00 [I,C*]; A23C0019-00 [I,C*]; A23L0001-00 [I,C*]; A23L0001-30 [I,C*]; A23L0002-52 [I,C*]; A23L0003-3463 [I,C*]; B01J0013-04 [I,C*]; B01J0013-06 [I,C*]; A21D0002-00 [I,A]; A23B0004-10 [I,A]; A23B0004-12 [I,A]; A23B0004-20 [I,A]; A23B0004-22 [I,A]; A23B0005-06 [I,A]; A23B0005-14 [I,A]; A23B0005-16 [I,A]; A23C0019-084 [I,A]; A23C0019-11 [I,A]; A23L0001-00 [I,A]; A23L0001-30 [I,A]; A23L0002-52 [I,A]; A23L0003-3463 [I,A]; A23L0003-3472 [I,A]; A23L0003-3544 [I,A]; A23L0003-3571 [I,A]; B01J0013-04 [I,A]; B01J0013-08 [I,A]
	ECLA	A21D002/00; A23B004/10; A23B004/12; A23B004/20; A23B004/22; A23B005/06; A23B005/14; A23B005/16; A23C019/084; A23C019/11; A23L001/00P4; A23L001/00P4B; A23L001/30F; A23L001/30M; A23L001/318B; A23L002/52; A23L003/3463A; A23L003/3472; A23L003/3544; A23L003/3571; B01J013/04B; B01J013/08
GB---2388581	IPCI	B01J0013-22 [ICM,7]; B01J0013-20 [ICM,7,C*]
	IPCR	A21D0002-00 [I,A]; A21D0002-00 [I,C*]; A23B0004-00 [I,C*]; A23B0004-10 [I,A]; A23B0004-12 [I,A]; A23B0004-12 [I,C*]; A23B0004-14 [I,C*]; A23B0004-20 [I,A]; A23B0004-22 [I,A]; A23B0005-00 [I,C*]; A23B0005-06 [I,A]; A23B0005-14 [I,A]; A23B0005-16 [I,A]; A23C0019-00 [I,C*]; A23C0019-084 [I,A]; A23C0019-11 [I,A]; A23L0001-00 [I,A]; A23L0001-00 [I,C*]; A23L0001-30 [I,A]; A23L0001-30 [I,C*]; A23L0002-52 [I,A]; A23L0002-52 [I,C*]; A23L0003-3463 [I,A]; A23L0003-3463 [I,C*]; A23L0003-3472 [I,A]; A23L0003-3544 [I,A]; A23L0003-3571 [I,A]; B01J0013-04 [I,A]; B01J0013-04 [I,C*]; B01J0013-06 [I,C*]; B01J0013-08 [I,A]; B01J0013-20 [I,C*]; B01J0013-22 [I,A]
	ECLA	A21D002/00; A23B004/10; A23B004/12; A23B004/20; A23B004/22; A23B005/06; A23B005/14; A23B005/16; A23C019/084; A23C019/11; A23L001/00P4; A23L001/00P4B; A23L001/30F; A23L001/30M; A23L002/52; A23L003/3463A; A23L003/3472; A23L003/3544; A23L003/3571; B01J013/04B; B01J013/08; B01J013/22
US2005042341	IPCI	C12H0001-10 [ICM,7]; C12H0001-00 [ICM,7,C*]
	IPCR	A21D0002-00 [I,A]; A21D0002-00 [I,C*]; A23B0004-00 [I,C*]; A23B0004-10 [I,A]; A23B0004-12 [I,A]; A23B0004-12 [I,C*]; A23B0004-14 [I,C*]; A23B0004-20 [I,A]; A23B0004-22 [I,A]; A23B0005-00 [I,C*]; A23B0005-06 [I,A]; A23B0005-14 [I,A]; A23B0005-16 [I,A]; A23C0019-00 [I,C*]; A23C0019-084 [I,A]; A23C0019-11 [I,A]; A23L0001-00 [I,A]; A23L0001-00 [I,C*]; A23L0001-30 [I,A]; A23L0001-30 [I,C*]; A23L0002-52 [I,A]; A23L0002-52 [I,C*]; A23L0003-3463 [I,A]; A23L0003-3463 [I,C*]; A23L0003-3472 [I,A]; A23L0003-3544 [I,A]; A23L0003-3571 [I,A]; B01J0013-04 [I,A]; B01J0013-04 [I,C*]; B01J0013-06 [I,C*]; B01J0013-08 [I,A]; B01J0013-20 [I,C*]; B01J0013-22 [I,A]
	NCL	426/321.000
	ECLA	A21D002/00; A23B004/10; A23B004/12; A23B004/20; A23B004/22; A23B005/06; A23B005/14; A23B005/16; A23C019/084; A23C019/11; A23L001/00P4; A23L001/00P4B; A23L001/30F; A23L001/30M; A23L002/52; A23L003/3463A;

A23L003/3472; A23L003/3544; A23L003/3571; B01J013/04B; B01J013/08; B01J013/22

EP---1663471 IPCI B01J0013-04 [ICM,7]; A23L0001-00 [ICS,7]
 ECLA A21D002/00; A23B004/10; A23B004/12; A23B004/20;
 A23B004/22; A23B005/06; A23B005/14; A23B005/16;
 A23C019/084; A23C019/11; A23L001/00P4; A23L001/00P4B;
 A23L001/30F; A23L001/30M; A23L001/318B; A23L002/52;
 A23L003/3463A; A23L003/3472; A23L003/3544;
 A23L003/3571; B01J013/04B; B01J013/08

AB The present invention relates to microcapsules, and more particularly to microcapsules where an aqueous bead or beads comprising the active ingredient is encapsulated in or by a hydrophobic shell matrix. The present invention relates also to novel methods for preparing the microcapsules according to the invention, as well as to the use of the microcapsules of the present invention as an additives in food industry and for pharmaceutical applications. A microcapsule of the present invention comprises a solidified hydrophobic shell matrix, an encapsulated aqueous bead or beads which is/are encapsulated in or by the solidified hydrophobic shell matrix, and an active ingredient or active ingredients dissolved or incorporated in the encapsulated aqueous bead or beads. For example, propionic acid was encapsulated first by mixing 250 g of propionic acid with 40 g of amidified low ester pectin (Danisco Pectin 2580) dissolved in 750 mL of water at 85°. This mixture was slowly incorporated into a mixture of 1333 g of a vegetable triglyceride (Grindsted PS 101, m.p. 58°) and 73 g of acetylated emulsifier (Acetem 50 00) melted at 85°. Following the incorporation of the aqueous mixture, a solution of 5 g of calcium chloride in 30 mL of water was added dropwise. The homogenization was maintained for 5 min and then a solution of 3 g of polysorbate 80 in 40 mL of water was added under constant mixing. The resulting low-viscosity water-in-oil emulsion was spray cooled to obtain a free flowing powder.

ST hydrocolloid bead encapsulation hydrophobic matrix microcapsule food pharmaceutical

IT Diglycerides
 Monoglycerides
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (C8-21 and C8-21-unsatd. monoglycerides and diglycerides, acetates, Grindsted Acetem 50-00; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT Fats and Glyceridic oils, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (animal, hydrogenated; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT Fats and Glyceridic oils, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (animal; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT Resin acids
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (esters; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT Fatty acids, biological studies
 Palm oil
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (hydrogenated; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT Analgesics
 Anti-inflammatory agents
 Antiarrhythmics
 Antibiotics
 Antihistamines

Antihypertensives
 Antimicrobial agents
 Antioxidants
 Antiparkinsonian agents
 Anxiolytics
 Coacervation
 Coloring materials
 Dammar
 Emulsifying agents
 Flavoring materials
 Food
 Gases
 Hydrocolloids
 Hypnotics and Sedatives
 Leavening agents
 Microcapsules
 Microorganism
 Nutrients
 Preservatives
 Sintering
 Tamarindus indica
 Thickening agents
 (microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)
 IT Acids, biological studies
 Bases, biological studies
 Carbohydrates, biological studies
 Diglycerides
 Enzymes, biological studies
 Fats and Glyceridic oils, biological studies
 Fossil waxes
 Gelatins, biological studies
 Hormones, animal, biological studies
 Monoglycerides
 Polymers, biological studies
 Proteins
 Resins
 Salts, biological studies
 Shellac
 Vitamins
 Waxes
 Zeins
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)
 IT Drug delivery systems
 (microcapsules; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)
 IT Encapsulation
 (microencapsulation; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)
 IT Caseins, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (sodium complexes; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)
 IT Proteins
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (soybean; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)
 IT Drug delivery systems
 (tablets, sustained-release; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)
 IT Drug delivery systems

(transdermal; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **Fatty acids, biological studies**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (unsatd.; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **Fats and Glyceridic oils, biological studies**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vegetable, hydrogenated; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **Waxes**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vegetable; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **Particles**
 (water-insol.; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **Proteins**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (whey; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **9002-18-0, Agar**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Agar NQS 200; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **9000-40-2, Locust bean gum**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (LBG 246 CAP; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **65546-99-8, High methoxyl pectin**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Pectin 1400; microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

IT **56-81-5D, Glycerin, esters 77-92-9, Citric acid, biological studies 79-09-4, Propionic acid, biological studies 79-41-4D, Methacrylic acid, copolymers 107-43-7, Betaine 110-44-1, Sorbic acid 126-13-6, Sucrose acetate isobutyrate 1414-45-5, Nisin 4075-81-4, Calcium propionate 7631-86-9, Silicon dioxide, biological studies 7647-14-5, Sodium chloride, biological studies 8063-16-9, Psyllium gum 9000-01-5, Arabic gum 9000-07-1, Carrageenan 9000-30-0, Guar gum 9000-47-9, Mesquite gum 9000-69-5, Pectin 9004-32-4, CMC 9004-34-6D, Cellulose, derivs. 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-61-9, Hyaluronic acid 9004-65-3, Hydroxypropyl methyl cellulose 9004-67-5, Methyl cellulose 9005-25-8, Starch, biological studies 9005-38-3, Alginate FD 175 9005-65-6, Polysorbate 80 9012-76-4, Chitosan 10043-52-4, Calcium chloride, biological studies 11114-20-8, κ-Carrageenan 11138-66-2, Xanthan 13463-67-7, Titanium dioxide, biological studies 71010-52-1, Gellan gum 82569-64-0 846569-33-3, Pectin 2580**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (microcapsules preparation by encapsulation of aqueous beads comprising active ingredient with hydrophobic shell matrix)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Akamatsu, T; US---5780056 A 1998 HCAPLUS
- (2) Allen, D; US2002061954 A1 2002 HCAPLUS
- (3) Biocompatibles Ltd; WO---8701587 A 1987 HCAPLUS
- (4) Jin, Y; WO2004041251 A 2004 HCAPLUS

- (5) Kydonieus, A; US---5580573 A 1996
 (6) Morgan, R; US---5204029 A 1993 HCAPLUS
 (7) Ncr Co; CH----509098 A 1971 HCAPLUS
 (8) Quong, D; US---6375968 B1 2002

L68 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:391294 HCAPLUS

DN 140:374306

ED Entered STN: 14 May 2004

TI Gel compositions as promoters for increasing the amount of blood plasma and foods containing them

IN Okazaki, Kazunari; Hayase, Hideki; Doi, Tatsuya; Nose, Hiroshi

PA Shinshu University, Japan; Ohtsuka Pharmaceutical Co., Ltd.

SO Jpn. Kokai Tokkyo Koho, 16 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

IC ICM A61K-0038/00

ICS A23L-0001/303; A23L-0001/305; A23L-0001/308; A61K-0009/06;
 A61K-0031/59; A61K-0031/70; A61K-0033/06; A61K-0047/36; A61K-0047/42;
 A61K-0047/44; A61P-0007/00; A61P-0007/08

CC 17-13 (Food and Feed Chemistry)

Section cross-reference(s): 18

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP2004137268	A2	20040513	2003JP-0332955	20030925 <--
	US2004137037	A1	20040715	2003US-0634125	20030805 <--
PRAI	2002JP-0283200	A	20020927	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
JP 2004137268	ICM	A61K-0038/00
	ICS	A23L-0001/303; A23L-0001/305; A23L-0001/308; A61K-0009/06; A61K-0031/59; A61K-0031/70; A61K-0033/06; A61K-0047/36; A61K-0047/42; A61K-0047/44; A61P-0007/00; A61P-0007/08
	IPCI	A61K0038-00 [ICM,7]; A23L0001-303 [ICS,7]; A23L0001-302 [ICS,7,C*]; A23L0001-305 [ICS,7]; A23L0001-308 [ICS,7]; A61K0009-06 [ICS,7]; A61K0031-59 [ICS,7]; A61K0031-70 [ICS,7]; A61K0033-06 [ICS,7]; A61K0047-36 [ICS,7]; A61K0047-42 [ICS,7]; A61K0047-44 [ICS,7]; A61P0007-00 [ICS,7]; A61P0007-08 [ICS,7]
	IPCR	A23L0001-302 [I,C*]; A23L0001-303 [I,A]; A23L0001-305 [I,A]; A23L0001-305 [I,C*]; A23L0001-308 [I,A]; A23L0001-308 [I,C*]; A61K0009-06 [I,A]; A61K0009-06 [I,C*]; A61K0031-59 [I,A]; A61K0031-59 [I,C*]; A61K0031-70 [I,A]; A61K0031-70 [I,C*]; A61K0033-06 [I,A]; A61K0033-06 [I,C*]; A61K0038-00 [I,A]; A61K0038-00 [I,C*]; A61K0047-36 [I,A]; A61K0047-36 [I,C*]; A61K0047-42 [I,A]; A61K0047-42 [I,C*]; A61K0047-44 [I,A]; A61K0047-44 [I,C*]; A61P0007-00 [I,A]; A61P0007-00 [I,C*]; A61P0007-08 [I,A]
	FTERM	4B018/MD04; 4B018/MD20; 4B018/MD23; 4B018/MD29; 4B018/MD36; 4B018/MD52; 4B018/MD71; 4B018/ME14; 4C076/AA09; 4C076/CC14; 4C076/CC40; 4C076/EE30T; 4C076/EE57T; 4C076/EE58T; 4C076/FF35; 4C084/AA02; 4C084/AA03; 4C084/BA44; 4C084/MA05; 4C084/MA28; 4C084/NA10; 4C084/ZA51; 4C086/AA01; 4C086/AA02; 4C086/DA14; 4C086/MA03; 4C086/MA05; 4C086/MA28; 4C086/NA10; 4C086/ZA51
US2004137037	IPCI	A61K0047-00 [ICM,7]
	IPCR	A61K0009-00 [I,A]; A61K0009-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-00 [I,C*]; A61K0033-06 [I,A]; A61K0033-06 [I,C*]
	NCL	424/439.000

ECLA A61K009/00M5F; A23L001/29F; A23L001/305D; A61K031/00;
A61K033/06

AB Title compns. with pH 3-4, useful for improvement of exercise ability, prevention of heat attack, etc., contain (hydrolyzed) proteins (noncoagulating at pH 3-4) 3-8, Ca 0.1-0.5, acidic seasonings 0.5-3, sugars 4-20, lipids 0-5, emulsifiers 0-0.5, agar 0.1-1, and water 65-90 weight%. Thus, a gel-type beverage comprising whey protein concentrate, gelatin peptide, milk Ca, citric acid, gluconic acid, phosphoric acid, sucrose, dextrin, soybean oil, glycerin fatty acid ester, agar, fruit juice, nondigestible reduced dextrin, and vitamin D significantly increased the amount of plasma in volunteers both in their early 20s and late 60s engaged in exercise on a bicycle ergometer.

ST protein calcium beverage gel blood plasma increase; exercise aging blood plasma increase whey protein; acid seasoning sugar lipid emulsifier agar blood plasma increase

IT Milk
(Ca of; blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT Condiments
(acidic; blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT Aging, animal
Blood plasma
Emulsifying agents
Exercise
Fruit and vegetable juices
Human
Milk preparations
(blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT Carbohydrates, biological studies
Lipids, biological studies
Proteins
Soybean oil
RL: BSU (Biological study, unclassified); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT Fatty acids, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(esters, with glycerin; blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT Beverages
Food
(gels; blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT Gelatins, biological studies
RL: BSU (Biological study, unclassified); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(hydrolyzates; blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT Oligosaccharides, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(nigero-; blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT Proteins
RL: BSU (Biological study, unclassified); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(whey; blood plasma amount-increasing gel foods for young and senior humans on exercise)

IT 57-50-1, Sucrose, biological studies 1406-16-2, Vitamin D
7440-70-2, Calcium, biological studies 9004-53-9,
Dextrin
RL: BSU (Biological study, unclassified); FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(blood plasma amount-increasing gel foods for young and senior humans on

exercise)
 IT 56-81-5D, Glycerin, fatty acid ester 77-92-9, Citric acid, biological studies 99-20-7, Trehalose 526-95-4, Gluconic acid 7664-38-2, Phosphoric acid, biological studies 9002-18-0, Agar 9004-53-9D, Dextrin, reduced, nondigestible
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (blood plasma amount-increasing gel foods for young and senior humans on exercise)

L68 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 1998:771332 HCAPLUS
 DN 130:24384
 ED Entered STN: 09 Dec 1998
 TI Viscous nondrying agent for treating food-handling surfaces
 IN Tyborski, Thomas; Luedecke, Werner
 PA Henkel-Ecolab G.m.b.H. und Co. o.H.G., Germany
 SO Ger. Offen., 8 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 IC ICM C09K-0003/00
 CC 17-4 (Food and Feed Chemistry)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE--19721590	A1	19981126	1997DE-1021590	19970523 <--
	CA---2291040	AA	19981126	1998CA-2291040	19980514 <--
	WO---9853021	A1	19981126	1998WO-EP02849	19980514 <--
	W: AU, BR, CA, CN, JP, MX, NZ, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU---9879126	A1	19981211	1998AU-0079126	19980514 <--
	AU---725810	B2	20001019		
	EP---983326	A1	20000308	1998EP-0929314	19980514 <--
	EP---983326	B1	20031112		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	BR---9809674	A	20000711	1998BR-0009674	19980514 <--
	NZ---501216	A	20010427	1998NZ-0501216	19980514 <--
	JP2001526721	T2	20011218	1998JP-0549914	19980514 <--
	AT---254157	E	20031115	1998AT-0929314	19980514 <--
	ZA---9804376	A	19991122	1998ZA-0004376	19980522 <--
	MX---9910520	A	20000531	1999MX-0010520	19991116 <--
	US2002136826	A1	20020926	1999US-0424401	19991123 <--
PRAI	1997DE-1021590	A	19970523	<--	
	1998WO-EP02849	W	19980514	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 19721590	ICM	C09K-0003/00
	IPCI	C09K0003-00 [ICM,6]
	IPCR	B08B0003-02 [I,C*]; B08B0003-02 [I,A]; A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,C*]; B05D0001-02 [I,A]; B05D0001-18 [I,C*]; B05D0001-18 [I,A]; B05D0001-28 [I,C*]; B05D0001-28 [I,A]; B05D0007-22 [I,C*]; B05D0007-22 [I,A]; B08B0003-04 [I,C*]; B08B0003-04 [I,A]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,C*]; C09D0005-00 [I,A]; C09K [I,S]; C09K0003-00 [I,C*]; C09K0003-00 [I,A]
CA---2291040	IPCI	C09K0003-00 [ICM,7]; C09D0005-00 [ICS,7]; B08B0017-02 [ICS,7]; B08B0017-00 [ICS,7,C*]; A21D0008-08 [ICS,7]; A21D0008-00 [ICS,7,C*]
	IPCR	B08B0003-02 [I,C*]; B08B0003-02 [I,A]; A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,C*]; B05D0001-02 [I,A]; B05D0001-18 [I,C*]; B05D0001-18 [I,A]; B05D0001-28 [I,C*]; B05D0001-28 [I,A];

B05D0007-22 [I,C*]; B05D0007-22 [I,A]; B08B0003-04 [I,C*]; B08B0003-04 [I,A]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,C*]; C09D0005-00 [I,A]; C09K [I,S]; C09K0003-00 [I,C*]; C09K0003-00 [I,A]
 WO---9853021 IPCI C09K0003-00 [ICM,6]; C09D0005-00 [ICS,6]; A21D0008-08 [ICS,6]; A21D0008-00 [ICS,6,C*]; B08B0017-02 [ICS,6]; B08B0017-00 [ICS,6,C*]
 IPCR B08B0003-02 [I,C*]; B08B0003-02 [I,A]; A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,C*]; B05D0001-02 [I,A]; B05D0001-18 [I,C*]; B05D0001-18 [I,A]; B05D0001-28 [I,C*]; B05D0001-28 [I,A]; B05D0007-22 [I,C*]; B05D0007-22 [I,A]; B08B0003-04 [I,C*]; B08B0003-04 [I,A]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,C*]; C09D0005-00 [I,A]; C09K [I,S]; C09K0003-00 [I,C*]; C09K0003-00 [I,A]
 AU---9879126 IPCI C09K0003-00 [ICM,6]; C09D0005-00 [ICS,6]; A21D0008-08 [ICS,6]; A21D0008-00 [ICS,6,C*]; B08B0017-02 [ICS,6]; B08B0017-00 [ICS,6,C*]
 IPCR B08B0003-02 [I,C*]; B08B0003-02 [I,A]; A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,C*]; B05D0001-02 [I,A]; B05D0001-18 [I,C*]; B05D0001-18 [I,A]; B05D0001-28 [I,C*]; B05D0001-28 [I,A]; B05D0007-22 [I,C*]; B05D0007-22 [I,A]; B08B0003-04 [I,C*]; B08B0003-04 [I,A]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,C*]; C09D0005-00 [I,A]; C09K [I,S]; C09K0003-00 [I,C*]; C09K0003-00 [I,A]
 EP----983326 IPCI C09K0003-00 [ICM,6]; C09D0005-00 [ICS,6]; A21D0008-08 [ICS,6]; A21D0008-00 [ICS,6,C*]; B08B0017-02 [ICS,6]; B08B0017-00 [ICS,6,C*]
 IPCR B08B0003-02 [I,C*]; B08B0003-02 [I,A]; A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,C*]; B05D0001-02 [I,A]; B05D0001-18 [I,C*]; B05D0001-18 [I,A]; B05D0001-28 [I,C*]; B05D0001-28 [I,A]; B05D0007-22 [I,C*]; B05D0007-22 [I,A]; B08B0003-04 [I,C*]; B08B0003-04 [I,A]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,C*]; C09D0005-00 [I,A]; C09K [I,S]; C09K0003-00 [I,C*]; C09K0003-00 [I,A]
 BR---9809674 IPCI C09K0003-00 [ICM,7]; C09D0005-00 [ICS,7]; A21D0008-08 [ICS,7]; A21D0008-00 [ICS,7,C*]; B08B0017-02 [ICS,7]; B08B0017-00 [ICS,7,C*]
 IPCR B08B0003-02 [I,C*]; B08B0003-02 [I,A]; A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,C*]; B05D0001-02 [I,A]; B05D0001-18 [I,C*]; B05D0001-18 [I,A]; B05D0001-28 [I,C*]; B05D0001-28 [I,A]; B05D0007-22 [I,C*]; B05D0007-22 [I,A]; B08B0003-04 [I,C*]; B08B0003-04 [I,A]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,C*]; C09D0005-00 [I,A]; C09K [I,S]; C09K0003-00 [I,C*]; C09K0003-00 [I,A]
 NZ---501216 IPCI C09K0003-00 [ICM,7]; C09D0005-00 [ICS,7]; A21D0008-08 [ICS,7]; A21D0008-00 [ICS,7,C*]; B08B0017-02 [ICS,7]; B08B0017-00 [ICS,7,C*]
 IPCR B08B0003-02 [I,C*]; B08B0003-02 [I,A]; A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,C*]; B05D0001-02 [I,A]; B05D0001-18 [I,C*]; B05D0001-18 [I,A]; B05D0001-28 [I,C*]; B05D0001-28 [I,A]; B05D0007-22 [I,C*]; B05D0007-22 [I,A]; B08B0003-04 [I,C*]; B08B0003-04 [I,A]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,C*]; C09D0005-00 [I,A]; C09K [I,S]; C09K0003-00 [I,C*]; C09K0003-00 [I,A]
 JP2001526721 IPCI C09K0003-00 [ICM,7]; B08B0003-02 [ICS,7]; B08B0003-04

[ICS,7]
 IPCR A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,A]; B05D0001-02 [I,C*]; B05D0001-18 [I,A]; B05D0001-18 [I,C*]; B05D0001-28 [I,A]; B05D0001-28 [I,C*]; B05D0007-22 [I,A]; B05D0007-22 [I,C*]; B08B0003-02 [I,A]; B08B0003-02 [I,C*]; B08B0003-04 [I,A]; B08B0003-04 [I,C*]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,A]; C09D0005-00 [I,C*]; C09K [I,S]; C09K0003-00 [I,A]; C09K0003-00 [I,C*]
 AT----254157 IPCI C09K0003-00 [ICM,7]; C09D0005-00 [ICS,7]; A21D0008-08 [ICS,7]; A21D0008-00 [ICS,7,C*]; B08B0017-02 [ICS,7]; B08B0017-00 [ICS,7,C*]
 ZA---9804376 IPCI C09K [ICM,6]
 IPCR B08B0003-02 [I,C*]; B08B0003-02 [I,A]; A21D0008-00 [I,C*]; A21D0008-08 [I,A]; B05D0001-02 [I,C*]; B05D0001-02 [I,A]; B05D0001-18 [I,C*]; B05D0001-18 [I,A]; B05D0001-28 [I,C*]; B05D0001-28 [I,A]; B05D0007-22 [I,C*]; B05D0007-22 [I,A]; B08B0003-04 [I,C*]; B08B0003-04 [I,A]; B08B0017-00 [I,C*]; B08B0017-02 [I,A]; C09D0005-00 [I,C*]; C09D0005-00 [I,A]; C09K [I,S]; C09K0003-00 [I,C*]; C09K0003-00 [I,A]
 MX---9910520 IPCI C09K0003-00 [ICM,5]; C09D0015-00 [ICS,5]; A21D0008-08 [ICS,5]; A21D0008-00 [ICS,5,C*]; B08B0017-02 [ICS,5]; B08B0017-00 [ICS,5,C*]
 US2002136826 IPCI B05D0007-22 [ICM,7]; B05D0001-02 [ICS,7]; B05D0001-28 [ICS,7]; B05D0001-18 [ICS,7]
 NCL 427/154.000; 106/002.000; 106/204.300; 106/205.900; 106/208.100; 427/230.000; 427/236.000; 427/239.000; 427/421.100; 427/427.700; 427/435.000
 AB A nondrying, viscous agent for treating food-handling surfaces contains 90-98.5 weight% water, 1-4 weight% hygroscopic material, 0.2-2 weight% preservative, and a thickening agent such that the Brookfield viscosity (number 3 spindle, 12 rpm) is 2000-10000 mPa. Thus, the agent may contain 96.8 weight% water, 2.0% weight% glycerol, 0.5 weight% sodium benzoate, and 0.7 weight% Me cellulose. The agent moistens food-handling surfaces and prevents drying of food and residues.
 ST food handling surface viscous nondrying agent; hygroscopic material food handling surface
 IT Flours and Meals
 Flours and Meals
 (Ceratonia siliqua; viscous nondrying agent for treating food-handling surfaces)
 IT Flours and Meals
 Flours and Meals
 (Cyamopsis tetragonolobus; viscous nondrying agent for treating food-handling surfaces)
 IT Fatty acids, biological studies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (calcium salts; viscous nondrying agent for treating food-handling surfaces)
 IT Fatty acids, biological studies
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (esters, with sucrose, mixture with glycerides; viscous nondrying agent for treating food-handling surfaces)
 IT Diglycerides
 Monoglycerides
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (esters; viscous nondrying agent for treating food-handling surfaces)
 IT Ceratonia siliqua
 Ceratonia siliqua
 Cyamopsis tetragonolobus
 Cyamopsis tetragonolobus
 (meal; viscous nondrying agent for treating food-handling surfaces)
 IT Caseins, biological studies

- RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(metal complexes; viscous nondrying agent for treating food-handling surfaces)
- IT **Glycerides, biological studies**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(mixture with sucrose fatty acid esters; viscous nondrying agent for treating food-handling surfaces)
- IT **Fatty acids, biological studies**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(potassium salts; viscous nondrying agent for treating food-handling surfaces)
- IT **Fatty acids, biological studies**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(sodium salts; viscous nondrying agent for treating food-handling surfaces)
- IT **Ceramics**
(surfaces; viscous nondrying agent for treating food-handling surfaces)
- IT **Glass, biological studies**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(surfaces; viscous nondrying agent for treating food-handling surfaces)
- IT **Carrageen (Chondrus crispus)**
Emulsifying agents
Food preservatives
Food processing
Hygroscopic substances
Thickening agents
(viscous nondrying agent for treating food-handling surfaces)
- IT **Albumins, biological studies**
Diglycerides
Gelatins, biological studies
Monoglycerides
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(viscous nondrying agent for treating food-handling surfaces)
- IT **1343-98-2, Silicic acid**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(colloidal; viscous nondrying agent for treating food-handling surfaces)
- IT **25618-55-7, Polyglycerol**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(esters with fatty acids; viscous nondrying agent for treating food-handling surfaces)
- IT **57-50-1D, Sucrose, fatty acid esters**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(mixture with glycerides; viscous nondrying agent for treating food-handling surfaces)
- IT **9005-25-8, Starch, biological studies**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(oxidized; viscous nondrying agent for treating food-handling surfaces)
- IT **9002-86-2, PVC 12597-69-2, Steel, biological studies**
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(surfaces; viscous nondrying agent for treating food-handling surfaces)
- IT **50-21-5D, Lactic acid, esters with mono- and diglycerides 56-81-5, Glycerol, biological studies 57-55-6, Propylene glycol, biological studies 64-18-6, Formic acid, biological studies 64-19-7D, Acetic acid, esters with mono- and diglycerides, biological studies 65-85-0, Benzoic acid, biological studies 77-92-9, Citric acid, biological studies 77-92-9D, Citric acid, esters with mono- and diglycerides 87-69-4D, Tartaric acid, esters with mono- and diglycerides, biological studies 94-13-3, Propyl p-hydroxybenzoate 99-76-3, Methyl p-hydroxybenzoate 110-44-1, Sorbic acid 120-47-8, Ethyl p-hydroxybenzoate 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 546-93-0, Magnesium carbonate 584-08-7, Potassium carbonate 1335-30-4, Aluminum silicate 1344-09-8, Sodium silicate 1344-28-1, Aluminum oxide, biological studies 1344-95-2, Calcium silicate 3812-32-6, Carbonate, biological studies 5026-62-0, Sodium methyl p-hydroxybenzoate**

7447-40-7, Potassium chloride, biological studies 9000-01-5, Gum arabic
 9000-65-1, Tragacanth 9000-69-5, Pectin 9002-18-0,
 Agar 9004-34-6, Cellulose, biological studies 9004-42-6,
 Carboxyethylcellulose 9004-64-2, Hydroxypropylcellulose 9004-65-3,
 Hydroxypropylmethylcellulose 9004-67-5, Methylcellulose 9005-32-7,
 Alginic acid 9005-35-0, Calcium alginate 9005-36-1,
 Potassium alginate 9005-37-2, Propylene glycol alginate 9005-38-3,
 Sodium alginate 9045-28-7, Starch acetate 10043-52-4, Calcium
 chloride, biological studies 11138-66-2, Xanthan 18262-01-6D, esters
 with mono- and diglycerides 35285-68-8, Sodium ethyl p-hydroxybenzoate
 35285-69-9, Sodium propyl p-hydroxybenzoate 51591-38-9D,
 Diacetyltartaric acid, esters with mono- and diglycerides 56645-02-4,
 Pectin amide 63798-35-6 68130-14-3, Acetylated distarch phosphate
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
 (viscous nondrying agent for treating food-handling surfaces)

L68 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1998:8328 HCAPLUS

DN 128:79976

ED Entered STN: 08 Jan 1998

TI Phytobiological preparations

PA Tomic, Dobrivoje, Germany

SO Ger. Offen., 6 pp.

CODEN: GWXXBX

DT Patent

LA German

IC ICM A61K-0035/78

ICS A61K-0033/42; A61K-0007/48

CC 63-4 (Pharmaceuticals)

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE--19622708	A1	19971211	1996DE-1022708	19960605 <--
	CA---2257559	AA	19971211	1997CA-2257559	19970602 <--
	WO---9746246	A1	19971211	1997WO-EP02849	19970602 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU---9731709	A1	19980105	1997AU-0031709	19970602 <--
	EP---914138	A1	19990512	1997EP-0927099	19970602 <--
	EP---914138	B1	20030312		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR---9709539	A	19990810	1997BR-0009539	19970602 <--
	JP2000514414	T2	20001031	1998JP-0500213	19970602 <--
	AT---234105	E	20030315	1997AT-0927099	19970602 <--
PRAI	1996DE-1022708	A	19960605	<--	
	1996DE-1048232	A	19961121	<--	
	1997WO-EP02849	W	19970602	<--	

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 19622708	ICM	A61K-0035/78
	ICS	A61K-0033/42; A61K-0007/48
	IPCI	A61K0035-78 [ICM,6]; A61K0033-42 [ICS,6]; A61K0007-48 [ICS,6]
	IPCR	A61K0033-42 [I,C*]; A61K0033-42 [I,A]
	ECLA	A61K033/42+M; A61K036/185+M; A61K036/28+M; A61K036/534+M; A61K036/736+M; A61K036/899+M
CA---2257559	IPCI	A61K0035-78 [ICM,6]; A61K0033-14 [ICS,6]; A61K0031-205 [ICS,6]; A61K0031-185 [ICS,6,C*]; A61K0033-42 [ICS,6]

WO---9746246

IPCR A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0031-185 [I,C*]; A61K0031-205 [I,A]; A61K0033-06 [I,C*]; A61K0033-08 [I,A]; A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-42 [I,C*]; A61K0033-42 [I,A]; A61K0036-185 [I,C*]; A61K0036-53 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-44 [I,C*]; A61K0047-44 [I,A]

ECLA A61K033/42+M; A61K036/534+M

IPCI A61K0035-78 [ICM,6]; A61K0033-14 [ICS,6]; A61K0031-205 [ICS,6]; A61K0031-185 [ICS,6,C*]; A61K0033-42 [ICS,6]

IPCR A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0031-185 [I,C*]; A61K0031-205 [I,A]; A61K0033-06 [I,C*]; A61K0033-08 [I,A]; A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-42 [I,C*]; A61K0033-42 [I,A]; A61K0036-185 [I,C*]; A61K0036-53 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-44 [I,C*]; A61K0047-44 [I,A]

AU---9731709

ECLA A61K033/42+M; A61K036/534+M

IPCI A61K0035-78 [ICM,6]; A61K0033-14 [ICS,6]; A61K0031-205 [ICS,6]; A61K0031-185 [ICS,6,C*]; A61K0033-42 [ICS,6]

IPCR A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0031-185 [I,C*]; A61K0031-205 [I,A]; A61K0033-06 [I,C*]; A61K0033-08 [I,A]; A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-42 [I,C*]; A61K0033-42 [I,A]; A61K0036-185 [I,C*]; A61K0036-53 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-44 [I,C*]; A61K0047-44 [I,A]

EP----914138

ECLA A61K033/42+M; A61K036/534+M

IPCI A61K0035-78 [ICM,6]; A61K0033-14 [ICS,6]; A61K0031-205 [ICS,6]; A61K0031-185 [ICS,6,C*]; A61K0033-42 [ICS,6]

IPCR A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0031-185 [I,C*]; A61K0031-205 [I,A]; A61K0033-06 [I,C*]; A61K0033-08 [I,A]; A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-42 [I,C*]; A61K0033-42 [I,A]; A61K0036-185 [I,C*]; A61K0036-53 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-44 [I,C*]; A61K0047-44 [I,A]

BR---9709539

ECLA A61K033/42+M; A61K036/534+M

IPCI A61K0035-78 [ICM,6]; A61K0033-14 [ICS,6]; A61K0031-205 [ICS,6]; A61K0031-185 [ICS,6,C*]; A61K0033-42 [ICS,6]

IPCR A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0031-185 [I,C*]; A61K0031-205 [I,A]; A61K0033-06 [I,C*]; A61K0033-08 [I,A]; A61K0033-14 [I,C*]; A61K0033-14 [I,A]; A61K0033-42 [I,C*]; A61K0033-42 [I,A]; A61K0036-185 [I,C*]; A61K0036-53 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61K0047-10 [I,C*]; A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A]; A61K0047-44 [I,C*]; A61K0047-44 [I,A]

JP2000514414

ECLA A61K033/42+M; A61K036/534+M

IPCI A61K0031-205 [ICM,7]; A61K0031-00 [ICS,7]; A61K0031-195 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0033-08 [ICS,7]; A61K0033-06 [ICS,7,C*]; A61K0033-14 [ICS,7]; A61K0033-42 [ICS,7]; A61K0035-78 [ICS,7]; A61K0045-06 [ICS,7]; A61K0045-00 [ICS,7,C*]; A61K0047-04 [ICS,7]; A61K0047-02 [ICS,7,C*]; A61K0047-10 [ICS,7]; A61K0047-14 [ICS,7]; A61K0047-36 [ICS,7]; A61K0047-44 [ICS,7]

AT----234105 ECLA A61K033/42+M; A61K036/534+M
 IPCI A61K0035-78 [ICM,7]; A61K0033-14 [ICS,7]; A61K0031-205
 [ICS,7]; A61K0031-185 [ICS,7,C*]; A61K0033-42 [ICS,7]
 IPCR A61K0047-02 [I,C*]; A61K0047-04 [I,A]; A61K0031-185
 [I,C*]; A61K0031-205 [I,A]; A61K0033-06 [I,C*];
 A61K0033-08 [I,A]; A61K0033-14 [I,C*]; A61K0033-14
 [I,A]; A61K0033-42 [I,C*]; A61K0033-42 [I,A];
 A61K0036-185 [I,C*]; A61K0036-53 [I,A]; A61K0045-00
 [I,C*]; A61K0045-06 [I,A]; A61K0047-10 [I,C*];
 A61K0047-10 [I,A]; A61K0047-14 [I,C*]; A61K0047-14
 [I,A]; A61K0047-36 [I,C*]; A61K0047-36 [I,A];
 A61K0047-44 [I,C*]; A61K0047-44 [I,A]
 ECLA A61K033/42+M; A61K036/534+M

AB Homeopathic phytobiol. preps. for topical, oral, or parenteral
 administration for treatment and prevention of pathol. conditions and
 alterations in cellular metabolism which contain a synergistic mixture of (a)
 ionic compds. and mineral salts, (b) astringents, binders, moisturizers,
 and essential oils, and (c) plant exts., gelation agents, acids,
 hyaluronidase, and other active agents. The ionic compds. and salts
 promote rapid penetration of the active components into the tissues. The
 preps. are useful for treatment of diarrhea, mastitis, and warts without
 use of antibiotics or cortisone. A suitable preparation contained Calendula
 0.1, Hamamelis 0.1, glycerin 2.0, NaCl 1.0, MgCl2 0.08, KCl 0.08,
 Na2HPO4.12H2O 0.6, agar 0.2, tannin 1.0, peppermint oil 0.05,
 and H2O to 100.0 weight%.

ST homeopathic phytobiol formulation salt

IT Fats and Glyceridic oils, biological studies
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (almond; phytobiol. preps.)

IT Skin preparations (pharmaceutical)
 (astringents; phytobiol. preps.)

IT Drug delivery systems
 (capsules; phytobiol. preps.)

IT Digestive tract
 Reproductive tract
 Tooth
 (disease; phytobiol. preps.)

IT Medical goods
 (dressings, homeopathic remedy-containing; phytobiol. preps.)

IT Drug delivery systems
 (emulsions; phytobiol. preps.)

IT Plant (Embryophyta)
 (exts.; phytobiol. preps.)

IT Drug delivery systems
 (gels; phytobiol. preps.)

IT Drug delivery systems
 (granules; phytobiol. preps.)

IT Drug delivery systems
 (homeopathic; phytobiol. preps.)

IT Drug delivery systems
 (hydrogels; phytobiol. preps.)

IT Alcohols, biological studies
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (lanolin, Eucerin; phytobiol. preps.)

IT Drug delivery systems
 (lotions; phytobiol. preps.)

IT Cosmetics
 (moisturizers; phytobiol. preps.)

IT Liquids
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oils; phytobiol. preps.)

IT Drug delivery systems
 (ointments, creams; phytobiol. preps.)

IT Drug delivery systems

(ointments; phytobiol. prepns.)

IT Drug delivery systems
(parenterals; phytobiol. prepns.)

IT Drug delivery systems
(pastes; phytobiol. prepns.)

IT Essential oils
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint; phytobiol. prepns.)

IT Antidiarrheals
Binders
Calendula
Cosmetics
Echinacea angustifolia
Emulsifying agents
Gelation agents
Hamamelis
Mastitis
Oat
Pigments, nonbiological
Surfactants
Urtica dioica
Uterus, disease
Veterinary medicine
Wart
(phytobiol. prepns.)

IT Acids, biological studies
Amino acids, biological studies
Enzymes, biological studies
Essential oils
Tannins
Vitamins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytobiol. prepns.)

IT Alcohols, biological studies
Chlorides, biological studies
Electrolytes, biological
Fats and Glyceridic oils, biological studies
Gelatin, biological studies
Lanolin
Paraffin oils
Petrolatum
Phosphates, biological studies
Salts, biological studies
Sulfates, biological studies
Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phytobiol. prepns.)

IT Drug delivery systems
(powders; phytobiol. prepns.)

IT Drug delivery systems
(solns.; phytobiol. prepns.)

IT Drug delivery systems
(sprays; phytobiol. prepns.)

IT Drug delivery systems
(tablets; phytobiol. prepns.)

IT Drug delivery systems
(topical; phytobiol. prepns.)

IT 57-13-6, Urea, biological studies 76-22-2, Camphor 1406-16-2, Vitamin D 9001-54-1, Hyaluronidase 11103-57-4, Vitamin A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phytobiol. prepns.)
 IT 56-81-5, 1,2,3-Propanetriol, biological studies 1309-48-4, Magnesium
 oxide, biological studies 7439-95-4D, Magnesium, salts, biological
 studies 7440-09-7D, Potassium, salts, biological studies 7440-23-5D,
 Sodium, salts, biological studies 7440-66-6D, Zinc, salts, biological
 studies 7440-70-2D, Calcium, salts, biological studies
 7447-40-7, Potassium chloride, biological studies 7647-14-5, Sodium
 chloride, biological studies 7720-78-7, Ferrous sulfate 7757-93-9,
 Calcium hydrogen phosphate 7758-87-4, Tricalcium phosphate
 7786-30-3, Magnesium chloride, biological studies 9000-69-5, Pectin
 9002-18-0, Agar 9005-25-8, Starch, biological studies
 10039-32-4, Disodium hydrogen phosphate dodecahydrate
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phytobiol. prepns.)

=> d his

(FILE 'HOME' ENTERED AT 14:41:55 ON 27 SEP 2006)

FILE 'HCAPLUS' ENTERED AT 14:42:55 ON 27 SEP 2006

L1 1 US2004137037/PN OR (US2003-634125 OR JP2002-283200)/AP,PRN

FILE 'WPIX' ENTERED AT 14:42:59 ON 27 SEP 2006

L2 1 L1

FILE 'STNGUIDE' ENTERED AT 14:43:08 ON 27 SEP 2006

FILE 'WPIX' ENTERED AT 15:06:52 ON 27 SEP 2006

L3 20735 (B04-B04A OR C04-B04A OR B04-B04A4 OR B04-B04A5 OR B04-B04A6 OR
 L4 31199 (B04-B04C1? OR C04-B04C1?)/MC OR V9?/M0,M1,M2,M3,M4,M5,M6
 L5 106391 (C07K OR A61K038)/IPC,IC,ICM,ICS,ICA,ICI
 L6 134584 L3-5
 L7 78597 A220/M0,M1,M2,M3,M4,M5,M6 OR E34-D?/MC OR C01F011/IPC,IC,ICM,IC
 L8 203212 L8?/M0,M1,M2,M3,M4,M5,M6 OR (B04-C02? OR C04-C02? OR A03-A?)/MC
 L9 38117 V77?/M0,M1,M2,M3,M4,M5,M6 OR (B04-B01B OR C04-B01B OR D10-A? OR
 L10 791 A61K031:77/IPC,IC,ICM,ICS,ICA,ICI
 L11 14345 (A03-A OR B04-C02D OR C04-B02D)/MC OR C08B037-12/IPC,IC,ICM,ICS
 L12 0 C08B037:12/IPC,IC,ICM,ICS,ICA,ICI
 L13 1360 L6 AND L7 AND L8
 L14 209 L13 AND L9
 L15 34 L14 AND L10-11
 L16 31 L15 AND ((M782 OR P86?)/M0,M1,M2,M3,M4,M5,M6 OR (B12-C09 OR C12
 L17 1 L15 AND A61K045/IPC,IC,ICM,ICS,ICA,ICI
 L18 31 L16-17
 E ORAZAKI K/AU
 E OKAZAKI K/AU
 L19 380 E3-6
 E HAYASE H/AU
 L20 5 E3
 E DOI T/AU
 L21 560 E3-4
 E NOSE H/AU
 L22 112 E3
 L23 5473 (SHINSU OR OTSUKA)/CS,PA
 L24 1850 SAKB/PACO
 L25 2 SHINSU/CS,PA
 L26 16962 SHIN-N/PACO
 L27 1 L18 AND L19-26
 L28 30 L18 NOT L27
 SEL AN 15-17
 L29 3 L28 AND E1-3
 E AGAR/CN
 L30 1 E3-5
 SEL SDCN
 EDIT /SDCN /DCN

L31 1053 E1
L32 753 86729-0-0-0/DCRE
L33 11876 AGAR
L34 3 L15 NOT L16
L35 13 L14 AND L31-33
SEL AN 1 11
L36 2 L35 AND E2-3
L37 6 L29,L36,L27
E WATER/CN
L38 14 E3-22
SEL SDCN L38
EDIT /SDCN /DCN
L39 9052 E1-14
SEL DCSE L38
EDIT /DCSE /DCRE
L40 6422 E15-28
L41 51285 (1543 OR 1740)/DRN
L42 QUE WATER OR AQUA OR H2O OR (HYDROGEN OR DIHYDROGEN) (1A) (MONOOX
L43 90 L14 AND L39-42
L44 6 L43 AND L31-33
L45 11 L37,L44

FILE 'REGISTRY' ENTERED AT 15:42:42 ON 27 SEP 2006

L46 1 AGAR/CN

FILE 'HCAPLUS' ENTERED AT 15:43:13 ON 27 SEP 2006

L47 7760 L46
L48 119012 AGAR OR AGARGEL OR AGAROSE OR "D 100" OR "S 10" OR "S 6" OR "S
E AGAR/CT
E E3+ALL
L49 7760 E9
E CARBOHYDRATES/CT
L50 QUE E3+OLD,NT
L51 QUE (POLYPEPTIDES+NT/CT OR PROTEIN#/CW,CT OR PROTEINS+OLD,NT1/C
E FATS/CT
E E3+ALL
E E2
L52 171464 E3+OLD,NT
E LIPIDS/CT
L53 525896 E3+OLD,NT1
E CALCIUM/CT
E E3+ALL
L54 377227 E10

FILE 'REGISTRY' ENTERED AT 15:48:24 ON 27 SEP 2006

L55 1 WATER/CN

FILE 'HCAPLUS' ENTERED AT 15:48:30 ON 27 SEP 2006

L56 QUE L55
L57 QUE WATER OR AQUA OR H2O OR (HYDROGEN OR DIHYDROGEN) (1A) (MONOOX
E WATER/CT
L58 QUE E3+OLD,NT
L59 QUE (PEPTIDES+NT/CT OR PROTEIN#/CW,CT OR PROTEINS+OLD,NT1/CT)
L60 QUE L59 AND L51
L61 116562 L60 AND L52-53
L62 11589 L61 AND (L54 OR CALCIUM OR CA)
L63 248 L62 AND L47-49
L64 82 L63 AND L56-58
L65 1 L64 AND L1
L66 66 L64 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L67 8 L66 AND EMULSIFYING AGENTS+OLD,NT/CT
SEL AN 1-2 7-8
L68 4 L67 AND E1-8

=>

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 26 Sep 2006 (20060926/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 168 tot

L68 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:182540 HCAPLUS

DN 142:266789

ED Entered STN: 04 Mar 2005

TI Microcapsules and their preparation

IN Coyne, Bob; Faragher, John; Gouin, Sebastien; Hansen, Crasten Bjorn; Ingram, Richard; Isak, Torben; Thomas, Linda Valerie; Tse, Kathryn Louise

PA Danisco A/S, Den.

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM B01J-0013/04

ICS A23L-0001/00

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 17

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005018794	A1	20050303	2004WO-GB03406	20040806 <--
	WO2005018794	C1	20060406		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	GB---2388581	A1	20031119	2003GB-0019817	20030822 <--
	US2005042341	A1	20050224	2004US-0820147	20040408 <--
	EP---1663471	A1	20060607	2004EP-0743676	20040806 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	2003GB-0019817	A	20030822	<--	
	2003US-497409P	P	20030822	<--	
	2003GB-0023335	A	20031006	<--	
	2003US-533053P	P	20031230	<--	
	2004US-560270P	P	20040408		
	2004US-0820147	A	20040408		
	2004WO-GB03406	W	20040806		

CLASS